abstract_id,session_title,abstract_title,ground_truth,expected_indication,litellm_gemini_indication_response,litellm_gemini_success,litellm_gemini_selected_source,litellm_gemini_confidence_score,litellm_gemini_reasoning,litellm_gemini_rules_retrieved,litellm_gemini_components_identified,litellm_gemini_quality_metrics_completeness,litellm_gemini_quality_metrics_rule_adherence,litellm_gemini_quality_metrics_clinical_accuracy,litellm_gemini_quality_metrics_formatting_compliance,litellm_gemini_llm_calls
147461,Myeloma And Other Monoclonal Gammopathies - Clinical,Depth Of Response And Mrd Status In Ultra High-Risk Myeloma And Plasma Cell Leukemia Treated With Dara-Cvrd And Augmented Autologous Transplant: Results Of The Risk-Stratified Uk Optimum/Muknine Trial,Ultra High-Risk;;Myeloma;;Plasma Cell Leukemia,Ultra High-Risk Myeloma;;Plasma Cell Leukemia,Ultra High-Risk Myeloma and Plasma Cell Leukemia,True,abstract_title,0.98,The indication is explicitly stated in the abstract title as the target condition for the treatment (Dara-Cvrd and Augmented Autologous Transplant). The text specifies 'Ultra High-Risk Myeloma' and 'Plasma Cell Leukemia'.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case rule: Capitalized significant words and lowercased conjunctions (and).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Verified Singular rule: Terms are already in singular form (Myeloma, Leukemia).""}]","[{""component"": ""Ultra High-Risk Myeloma"", ""type"": ""Disease Subtype"", ""normalized_form"": ""Ultra High-Risk Myeloma"", ""rule_applied"": ""Preserved risk stratification modifier as per text; applied Title Case.""}, {""component"": ""Plasma Cell Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Plasma Cell Leukemia"", ""rule_applied"": ""Extracted as distinct entity; applied Title Case.""}]",1.0,1.0,1.0,1.0,0
147482,Myeloproliferative Neoplasms - Clinical,Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis (Mf) Therapy And After Prior Ruxolitinib (Rux): Results From The Jakarta And Jakarta2 Trials,First-Line;;Myelofibrosis,First-Line Myelofibrosis,Myelofibrosis,True,Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis (Mf) Therapy And After Prior Ruxolitinib (Rux): Results From The Jakarta And Jakarta2 Trials,0.95,"The abstract title explicitly mentions 'Myelofibrosis (Mf)' as the target condition for the therapy. The term 'Myeloproliferative Neoplasms' in the session title is a broader category, but the specific indication studied is Myelofibrosis. Abbreviations like '(Mf)' and '(Rux)' are removed. Line of therapy details ('First-Line', 'After Prior Ruxolitinib') are excluded to extract the core medical indication. The output follows Title Case and Singular rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form.""}]","[{""component"": ""Myelofibrosis"", ""type"": ""Disease"", ""normalized_form"": ""Myelofibrosis"", ""rule_applied"": ""Extracted specific disease term, converted to Title Case""}, {""component"": ""(Mf)"", ""type"": ""Abbreviation"", ""normalized_form"": """", ""rule_applied"": ""Removed abbreviation""}]",1.0,1.0,1.0,1.0,0
180260,"Clonal Hematopoiesis, Aging and Inflammation: Poster I",Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis,RUNX1-Familial Platelet Disorder;;Myeloid Malignancies,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy,RUNX1-Familial Platelet Disorder with Myeloid Malignancy,True,RUNX1-Familial Platelet Disorder with Myeloid Malignancies,0.95,The specific condition identified is 'RUNX1-Familial Platelet Disorder with Myeloid Malignancies'. Following standard formatting rules: 1. 'RUNX1' is preserved as a gene symbol. 2. 'Familial Platelet Disorder' is kept in Title Case. 3. The preposition 'with' is lowercased. 4. The plural 'Malignancies' is converted to the singular 'Malignancy' based on general singularization rules.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Title case applied; 'RUNX1' preserved as gene symbol; 'with' lowercased.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Singularization rule applied to convert 'Malignancies' to 'Malignancy'.""}]","[{""component"": ""RUNX1"", ""type"": ""Gene Symbol"", ""normalized_form"": ""RUNX1"", ""rule_applied"": ""Preserve Acronyms/Gene Symbols""}, {""component"": ""Familial Platelet Disorder"", ""type"": ""Disease Name"", ""normalized_form"": ""Familial Platelet Disorder"", ""rule_applied"": ""Title Case""}, {""component"": ""with"", ""type"": ""Preposition"", ""normalized_form"": ""with"", ""rule_applied"": ""Lowercase Prepositions""}, {""component"": ""Myeloid Malignancies"", ""type"": ""Disease Class"", ""normalized_form"": ""Myeloid Malignancy"", ""rule_applied"": ""Singularization""}]",1.0,1.0,0.98,1.0,0
147495,Sickle Cell Disease,The Burden Of Sickle Cell Disease (Scd) On Patients In Ghana And Nigeria Compared With Other Low-/Middle-Income And High-Income Countries: Results From The Sickle Cell World Assessment Survey (Sway),Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,0.98,The abstract title explicitly states 'The Burden Of Sickle Cell Disease (Scd)'. 'Sickle Cell Disease' is the primary medical condition. The extracted term is formatted in Title Case according to the retrieved Casing rule. Demographic information ('Patients In Ghana And Nigeria') and survey names ('Sickle Cell World Assessment Survey') are excluded as they do not constitute the clinical indication itself.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Rule 1 (ID: 7): Convert finalized medical-indication phrase to Title Case (capitalize the first letter of each clinically significant word).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Applied Rule 2 (ID: 8): Ensure the indication is in the Singular form (though input was already singular, rule verifies compliance).""}]","[{""component"": ""Sickle Cell Disease"", ""type"": ""Disease Name"", ""normalized_form"": ""Sickle Cell Disease"", ""rule_applied"": ""Title Case Conversion""}, {""component"": ""Scd"", ""type"": ""Abbreviation"", ""normalized_form"": ""Sickle Cell Disease"", ""rule_applied"": ""Abbreviation Resolution""}]",1.0,1.0,1.0,1.0,0
262190,Chronic lymphocytic leukemia and related disorders - Clinical,"Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor Of Wild-Type And C481S Mutated Bruton Tyrosine Kinase For B-Cell Malignancies: Efficacy And Safety Of The Phase 2 Dose-Expansion Bellwave-001 Study",B-Cell Malignancies,B-Cell Malignancy,B-Cell Malignancy,True,Abstract Title,0.98,"The indication was extracted from the abstract title phrase 'For B-Cell Malignancies'. According to the retrieved rules, the indication was normalized to the singular form ('Malignancies' to 'Malignancy') and formatted in Title Case ('B-Cell Malignancy').","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To apply Title Case formatting, capitalizing clinically significant words (e.g., 'B-Cell Malignancy').""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert plural disease terms (e.g., 'Malignancies') to their clinically accepted singular forms.""}]","[{""component"": ""B-Cell Malignancies"", ""type"": ""Disease"", ""normalized_form"": ""B-Cell Malignancy"", ""rule_applied"": ""Singularization and Title Case""}]",1.0,1.0,1.0,1.0,0
327727,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients,Newly Diagnosed;;AML,Newly Diagnosed Acute Myeloid Leukemia,Newly diagnosed acute myeloid leukemia,True,abstract_title,0.98,The abstract title specifically mentions 'Newly Diagnosed AML Patients'. The abbreviation AML is expanded to Acute Myeloid Leukemia. The term 'Patients' is excluded based on standard indication extraction rules. The indication is formatted in sentence case.,"[{""category"": ""Disease/Condition"", ""subcategories"": [""Acronyms"", ""General""], ""reason"": ""To expand 'AML' to 'Acute myeloid leukemia' and verify standard disease nomenclature.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General"", ""Line of Therapy""], ""reason"": ""To identify and retain 'Newly diagnosed' as a critical modifier of the indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""Cleanup""], ""reason"": ""To apply sentence casing and remove the word 'Patients'.""}]","[{""component"": ""Newly Diagnosed"", ""type"": ""Line of Therapy / Condition Status"", ""normalized_form"": ""Newly diagnosed"", ""rule_applied"": ""Retain modifier""}, {""component"": ""AML"", ""type"": ""Disease"", ""normalized_form"": ""acute myeloid leukemia"", ""rule_applied"": ""Expand acronym""}, {""component"": ""Patients"", ""type"": ""Population"", ""normalized_form"": """", ""rule_applied"": ""Remove stop word""}]",1.0,1.0,1.0,1.0,0
327732,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome,Adult;;AML,Adult Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia,True,abstract_title,0.96,The abstract title explicitly identifies 'Adult AML' as the condition being studied. The abbreviation 'AML' is expanded to 'Acute Myeloid Leukemia' for standard clinical representation. The term 'Adult' is retained as it defines the specific patient population. The formatting follows the retrieved Title Case rule.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Convert finalized medical-indication phrase to Title Case (capitalize first letter of clinically significant words).""}]","[{""component"": ""Adult"", ""type"": ""Patient Sub-Group"", ""normalized_form"": ""Adult"", ""rule_applied"": ""Clinical specificity retention""}, {""component"": ""AML"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Abbreviation expansion""}]",1.0,1.0,1.0,1.0,0
147508,Stem Cell Transplantation - Clinical,Belumosudil For Chronic Graft-Versus Host Disease After 2 Or More Prior Lines Of Therapy: The Rockstar Study (Kd025-213),Chronic;;Graft-Versus Host Disease,Chronic Graft-Versus Host Disease,Chronic Graft-Versus Host Disease After 2 or More Prior Lines of Therapy,True,abstract_title,0.95,"The indication is explicitly stated in the abstract title as 'Chronic Graft-Versus Host Disease After 2 Or More Prior Lines Of Therapy'. The drug name 'Belumosudil' and the study name 'The Rockstar Study' are excluded. The text is normalized to Title Case, ensuring conjunctions and prepositions are lowercase (e.g., 'or', 'of').","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Used to apply Title Case formatting to the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Used to ensure singular formatting where applicable.""}]","[{""component"": ""Chronic Graft-Versus Host Disease"", ""type"": ""Disease"", ""normalized_form"": ""Chronic Graft-Versus Host Disease"", ""rule_applied"": ""Title Case""}, {""component"": ""After 2 Or More Prior Lines Of Therapy"", ""type"": ""Patient Sub-Group"", ""normalized_form"": ""After 2 or More Prior Lines of Therapy"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
147511,Stem Cell Transplantation - Clinical,Narsoplimab (Oms721) Treatment Contributes To Improvements In Organ Function In Adult Patients With High-Risk Transplant-Associated Thrombotic Microangiopathy,,,High-risk transplant-associated thrombotic microangiopathy,True,Abstract Title,0.95,The indication is explicitly stated in the abstract title as the condition being treated by Narsoplimab. The phrase 'High-Risk Transplant-Associated Thrombotic Microangiopathy' represents the specific disease state. 'Adult Patients' indicates the population but is typically secondary to the disease name in indication headers unless the indication is exclusively restricted.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To standardize capitalization to sentence case and verify general formatting requirements.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Age group""], ""reason"": ""To evaluate whether the demographic 'Adult Patients' should be part of the primary indication string.""}]","[{""component"": ""High-Risk"", ""type"": ""Severity Modifier"", ""normalized_form"": ""High-risk"", ""rule_applied"": ""Sentence casing for modifiers""}, {""component"": ""Transplant-Associated Thrombotic Microangiopathy"", ""type"": ""Disease"", ""normalized_form"": ""transplant-associated thrombotic microangiopathy"", ""rule_applied"": ""Sentence casing for disease names""}]",1.0,1.0,1.0,1.0,0
213047,Geriatric Urological Society (GUS),Parkinson's Disease and the Impact on Urologic Health in Older Adults,Parkinson's Disease;;Older Adults,Elderly Parkinson's Disease,Parkinson's Disease,True,abstract_title,0.95,"The abstract title explicitly names 'Parkinson's Disease' as the primary medical condition. The phrase 'Impact on Urologic Health' describes the study's focus/outcome rather than the indication itself. The demographic term 'Older Adults' is excluded from the indication string as per patient subgroup exclusion rules, unless it constitutes a specific disease subtype.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Convert every finalized medical-indication phrase to Title Case\u2014capitalize the first letter of each clinically significant word.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Geriatric""], ""reason"": ""Demographic descriptors such as 'Older Adults' are generally excluded from the indication unless they are part of a fixed disease name.""}]","[{""component"": ""Parkinson's Disease"", ""type"": ""Disease"", ""normalized_form"": ""Parkinson's Disease"", ""rule_applied"": ""Title Case""}, {""component"": ""Older Adults"", ""type"": ""Patient Subgroup"", ""normalized_form"": ""Geriatric"", ""rule_applied"": ""Exclude Patient Subgroup""}]",1.0,1.0,1.0,1.0,0
327741,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age,NPM1;;Mutant;;AML,NPM1-Mutant Acute Myeloid Leukemia,NPM1-mutated acute myeloid leukemia,True,Abstract Title: Intensive Therapy for NPM1 Mutant AML Patients...,0.95,The abstract title explicitly identifies the patient population as 'NPM1 Mutant AML Patients'. The indication is standardized by expanding the abbreviation 'AML' to 'acute myeloid leukemia' and formatting the mutation status 'NPM1 Mutant' to 'NPM1-mutated' according to standard clinical nomenclature rules.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""Abbreviations""], ""reason"": ""To ensure correct capitalization of the disease name and expansion of the 'AML' acronym.""}, {""category"": ""Biomarkers"", ""subcategories"": [""Gene symbols"", ""Mutation status""], ""reason"": ""To standardize the formatting of the 'NPM1' gene and its 'Mutant' status to 'NPM1-mutated'.""}]","[{""component"": ""AML"", ""type"": ""Disease"", ""normalized_form"": ""acute myeloid leukemia"", ""rule_applied"": ""Abbreviation Expansion""}, {""component"": ""NPM1 Mutant"", ""type"": ""Biomarker"", ""normalized_form"": ""NPM1-mutated"", ""rule_applied"": ""Mutation Status Formatting""}]",1.0,1.0,1.0,1.0,0
180285,Bone Marrow Failure: Poster I,Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy,Severe Aplastic Anemia,Severe Aplastic Anemia,Severe aplastic anemia,True,abstract_title,0.98,"The medical condition is explicitly identified as 'Severe Aplastic Anemia' in the abstract title. The text 'Chinese Patients' represents a demographic subgroup which is typically excluded from the core indication unless the disease is specific to that ethnicity. The treatment 'Eltrombopag and Intensive Immunosupressive Therapy' is the intervention, not the indication. Standard sentence casing was applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To apply sentence case formatting and check for general extraction guidelines.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Demographics""], ""reason"": ""To handle the presence of specific patient population descriptors like 'Chinese Patients'.""}]","[{""component"": ""Severe Aplastic Anemia"", ""type"": ""Disease/Condition"", ""normalized_form"": ""Severe aplastic anemia"", ""rule_applied"": ""Sentence case transformation""}, {""component"": ""Chinese Patients"", ""type"": ""Demographic"", ""normalized_form"": ""Excluded"", ""rule_applied"": ""Exclude patient subgroup unless necessary""}]",1.0,1.0,1.0,1.0,0
294973,MSD - Navigating through the rapidly evolving treatment landscape for GI Cancers - A Clinical & Patient Centric Approach towards implementing Immunotherapy,Changing GEC Patient Care with IO plus Chemotherapy in First-Line,GI Cancers;;First-Line,First-Line Gastrointestinal Cancer,First-Line Gastroesophageal Cancer,True,Abstract Title,0.95,The abstract title provides a more specific disease definition ('GEC' vs 'GI Cancers') and clearly specifies the line of therapy ('First-Line'). 'GEC' was expanded to 'Gastroesophageal Cancer' and formatted to Title Case and Singular form according to the retrieved rules.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case (capitalizing significant words).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert plural disease terms to their clinically accepted singular form (Singularization).""}]","[{""component"": ""GEC"", ""type"": ""Disease"", ""normalized_form"": ""Gastroesophageal Cancer"", ""rule_applied"": ""Abbreviation Expansion / Singularization""}, {""component"": ""First-Line"", ""type"": ""Treatment Line"", ""normalized_form"": ""First-Line"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
262206,Chronic myeloid leukemia - Clinical,Bosutinib Dose Optimization In The Second-Line Treatment Of Elderly Cml Patients: Extended 3-Year Follow-Up And Final Results Of The Best Study,Second-Line;;Elderly;;Cml,Second-Line Elderly Chronic Myeloid Leukemia,Chronic Myeloid Leukemia,True,abstract_title,0.98,The abstract title identifies 'Cml' (Chronic Myeloid Leukemia) as the condition treated. The session title confirms the full disease name. The indication is normalized to Title Case and Singular form based on standard clinical rules. Qualifiers such as 'Elderly' (Patient Sub-Group) and 'Second-Line Treatment' (Line of Therapy) provide context but the core medical indication is the disease entity.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Convert finalized medical-indication phrase to Title Case (Rule 7).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Convert plural terms to singular (Rule 8) and handle abbreviations.""}]","[{""component"": ""Chronic myeloid leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Chronic Myeloid Leukemia"", ""rule_applied"": ""Title Case""}, {""component"": ""Cml"", ""type"": ""Abbreviation"", ""normalized_form"": ""Chronic Myeloid Leukemia"", ""rule_applied"": ""Expansion""}, {""component"": ""Elderly"", ""type"": ""Patient Sub-Group"", ""normalized_form"": ""Elderly"", ""rule_applied"": ""Extraction""}, {""component"": ""Second-Line Treatment"", ""type"": ""Line of Therapy"", ""normalized_form"": ""Second-line Treatment"", ""rule_applied"": ""Extraction""}]",1.0,1.0,1.0,1.0,0
147521,Thrombosis And Vascular Biology - Biology & Translational Research,Thrombophilia As Risk Factor For Asparaginase Related Venous Thromboembolism In Pediatric And Young Adult Patients Affected By Acute Lymphoblastic Leukemia,Venous Thromboembolism;;Pediatric;;Young Adult,Pediatric Young Adult Venous Thromboembolism,Acute Lymphoblastic Leukemia,True,abstract_title,0.95,"The abstract title explicitly identifies the patient population as those 'Affected By Acute Lymphoblastic Leukemia'. While 'Venous Thromboembolism' and 'Thrombophilia' are mentioned, they function as a complication and a risk factor respectively, not the primary indication for the patient population. Demographic descriptors ('Pediatric And Young Adult') modify 'Patients' rather than the disease name directly, so the core disease name is extracted. Standard formatting rules (Title Case, Singular) are applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Rule 7 (Title case): Ensures the final indication is in Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Rule 8 (Singular): Ensures the indication is in the singular form (though 'Leukemia' is already singular).""}]","[{""component"": ""Acute Lymphoblastic Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Acute Lymphoblastic Leukemia"", ""rule_applied"": ""Extraction based on 'Affected By' context""}, {""component"": ""Pediatric And Young Adult"", ""type"": ""Population"", ""normalized_form"": ""Pediatric And Young Adult"", ""rule_applied"": ""Excluded (Demographic descriptor)""}, {""component"": ""Venous Thromboembolism"", ""type"": ""Condition"", ""normalized_form"": ""Venous Thromboembolism"", ""rule_applied"": ""Excluded (Complication/Secondary Condition)""}, {""component"": ""Thrombophilia"", ""type"": ""Condition"", ""normalized_form"": ""Thrombophilia"", ""rule_applied"": ""Excluded (Risk Factor)""}]",1.0,1.0,1.0,1.0,0
393283,Developmental Therapeutics,"A Phase I Study Of Safety, Pharmacokinetics, And Pharmacodynamics Of Scr-6920, A Protein Arginine Methyltransferase 5(Prmt5) Inhibitor, In Patients With Advanced Malignant Tumors",Advanced;;Malignant Tumors,Advanced Malignant Tumor,Advanced Malignant Tumor,True,"A Phase I Study Of Safety, Pharmacokinetics, And Pharmacodynamics Of Scr-6920, A Protein Arginine Methyltransferase 5(Prmt5) Inhibitor, In Patients With Advanced Malignant Tumors",0.98,"The indication was extracted from the phrase 'In Patients With Advanced Malignant Tumors' found in the abstract title. The rules for singularization were applied to convert 'Tumors' to 'Tumor', and Title Case formatting was applied according to the 'Common Check points' rules.","[{""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Applied singularization rule to convert plural disease terms (e.g., 'tumors') to their singular form ('Tumor').""}, {""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case formatting to the final indication string.""}]","[{""component"": ""Advanced Malignant Tumors"", ""type"": ""Raw Extraction"", ""normalized_form"": ""Advanced Malignant Tumor"", ""rule_applied"": ""Singularization""}]",1.0,1.0,1.0,1.0,0
262209,Chronic myeloid leukemia - Clinical,Real-Life Outcomes Of Ponatinib Treatment In Patients With Chronic Myeloid Leukemia (Cml) Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All): 5-Year-Data From A Belgian Registry,Chronic Myeloid Leukemia;;Philadelphia Chromosome-Positive;;Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia;;Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,True,Real-Life Outcomes Of Ponatinib Treatment In Patients With Chronic Myeloid Leukemia (Cml) Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All): 5-Year-Data From A Belgian Registry,1.0,"The abstract title explicitly identifies the patient population as those with 'Chronic Myeloid Leukemia (Cml)' or 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All)'. These are extracted as the medical indications. Following the retrieval of rules, the indications are formatted in Title Case and Singular form. The abbreviation '(Cml)' and '(Ph+All)' are removed in favor of the full normalized disease names, or if kept, would be redundant to the full text; standard practice usually extracts the full term. Multiple indications are separated by ';;'.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case (e.g., 'Chronic Myeloid Leukemia').""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the Singular form and plural terms are converted if necessary.""}]","[{""component"": ""Chronic Myeloid Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Chronic Myeloid Leukemia"", ""rule_applied"": ""Title Case""}, {""component"": ""Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
180298,Bone Marrow Failure: Poster I,"Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria",Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria,True,abstract_title,1.0,"The abstract title explicitly states the study involves patients with 'Paroxysmal Nocturnal Hemoglobinuria'. The indication is extracted directly from this phrase. Standard casing rules (Title Case) and singularization rules were applied, although the term was already in the correct format.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication 'Paroxysmal Nocturnal Hemoglobinuria' is formatted in Title Case as per standard medical indication requirements.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form if applicable (Rule ID 8).""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Checked for potential modifiers (e.g., 'De Novo', 'Persistent', 'Relapsed') to determine if a specific patient subgroup was indicated; none were applicable.""}]","[{""component"": ""Pozelimab"", ""type"": ""Drug"", ""normalized_form"": ""Pozelimab"", ""rule_applied"": ""N/A""}, {""component"": ""Paroxysmal Nocturnal Hemoglobinuria"", ""type"": ""Disease"", ""normalized_form"": ""Paroxysmal Nocturnal Hemoglobinuria"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
393291,Developmental Therapeutics,"Preclinical Evaluation Of Hlx42, A Novel Egfr-Targeting Adc, For Cetuximab Or Tki Resistant Cancer",Cancer,Cancer,Cetuximab or TKI Resistant Cancer,True,abstract_title,0.95,"The indication was extracted from the abstract title phrase 'For Cetuximab Or Tki Resistant Cancer'. The study type ('Preclinical Evaluation') and drug information ('Hlx42, A Novel Egfr-Targeting Adc') were excluded to isolate the target condition.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Ensure the indication starts with a capital letter and acronyms like TKI are preserved.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Resistance""], ""reason"": ""Include resistance markers (Cetuximab or TKI resistant) as they define the specific patient population targeted.""}]","[{""component"": ""Cetuximab or TKI Resistant"", ""type"": ""Modifier"", ""normalized_form"": ""Cetuximab or TKI resistant"", ""rule_applied"": ""Keep resistance modifiers""}, {""component"": ""Cancer"", ""type"": ""Disease"", ""normalized_form"": ""Cancer"", ""rule_applied"": ""Standardize disease term""}]",1.0,1.0,0.95,1.0,0
180300,Bone Marrow Failure: Poster I,Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry,Adult;;Late-Onset;;Telomere Biology Disorders,Adult Late-Onset Telomere Biology Disorder,Adult Late-Onset Telomere Biology Disorder,True,Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry,0.98,"The indication was extracted from the abstract title as it contains the specific patient population and condition. The phrase 'Adult Late-Onset Telomere Biology Disorders' was identified. Following the retrieved rules, the plural 'Disorders' was converted to the singular 'Disorder' (Rule ID 8), and the entire string was formatted in Title Case (Rule ID 7). 'Adult' and 'Late-Onset' were retained as they describe a specific clinical subgroup of the condition.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication follows standard capitalization rules (Title Case).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To handle pluralization and ensure the indication is in the singular form.""}]","[{""component"": ""Adult Late-Onset Telomere Biology Disorders"", ""type"": ""Condition"", ""normalized_form"": ""Adult Late-Onset Telomere Biology Disorder"", ""rule_applied"": ""Singular (ID: 8)""}]",1.0,1.0,1.0,1.0,0
327760,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies,Newly Diagnosed;;IDH;;TP53;;Co-Mutated;;AML,Newly Diagnosed IDH-Mutated TP53-Mutated Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,Abstract Title,0.95,"The abstract title identifies the condition as 'Newly Diagnosed IDH/TP53 Co-Mutated AML'. The core disease entity is 'AML', which stands for Acute Myeloid Leukemia. Terms like 'Newly Diagnosed' (line of therapy/state) and 'IDH/TP53 Co-Mutated' (molecular biomarkers) describe the specific patient population but the primary medical indication is the disease itself. The casing has been normalized to Title Case per standard clinical rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Acronyms"", ""Casing""], ""reason"": ""To handle the acronym 'AML' and ensure Title Case formatting for the final indication.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Checked for rules regarding patient sub-group modifiers like 'Newly Diagnosed' (similar to 'De Novo' or 'Prior') to determine inclusion/exclusion.""}]","[{""component"": ""AML"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Acronym Expansion""}, {""component"": ""Newly Diagnosed"", ""type"": ""Patient Sub-Group"", ""normalized_form"": ""Newly Diagnosed"", ""rule_applied"": ""Contextual Exclusion (Line of Therapy)""}, {""component"": ""IDH/TP53 Co-Mutated"", ""type"": ""Biomarker"", ""normalized_form"": ""IDH/TP53 Co-Mutated"", ""rule_applied"": ""Biomarker Extraction""}]",1.0,1.0,0.98,1.0,0
311376,"Abstracts: RA - Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease",Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity,RA ,Rheumatoid Arthritis,Rheumatoid Arthritis,True,"Abstracts: RA - Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity",0.95,The input text explicitly mentions 'RA' (Rheumatoid Arthritis) in both the session title and abstract title. The text discusses 'Classified RA' and 'Pre- and Early Disease' in the context of RA. The abbreviation 'RA' is expanded to the full disease name 'Rheumatoid Arthritis' following standard clinical indication practices. The indication is formatted in Title Case as per the casing rule.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine the casing format (Title Case) for the indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure singular formatting and handling of plural terms if applicable.""}]","[{""component"": ""RA"", ""type"": ""Abbreviation"", ""normalized_form"": ""Rheumatoid Arthritis"", ""rule_applied"": ""Expansion of disease abbreviation to full clinical name""}, {""component"": ""Classified RA"", ""type"": ""Disease Term"", ""normalized_form"": ""Rheumatoid Arthritis"", ""rule_applied"": ""Normalization to core disease entity""}]",1.0,1.0,1.0,1.0,0
229467,Vaccines and Immunity against Bacteria and Parasites,"The novel adjuvant, ADA-1, restores age-associated defects in the adaptive immune response to Clostridioides difficile infection and vaccination in an aging mouse model",Clostridioides difficile infection,Clostridioides Difficile Infection,Clostridioides Difficile Infection,True,"The novel adjuvant, ADA-1, restores age-associated defects in the adaptive immune response to Clostridioides difficile infection and vaccination in an aging mouse model",0.96,"The text identifies 'Clostridioides difficile infection' as the specific condition being targeted by the vaccination strategy involving the novel adjuvant ADA-1. While 'vaccination' and 'aging' are mentioned, they represent the intervention modality and the patient subgroup (or model equivalent) respectively, not the core indication. The extracted condition was normalized to Title Case and verified to be in Singular form based on the retrieved rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Rule 1 (ID: 7) to convert the indication to Title Case (Capitalizing 'Clostridioides', 'Difficile', and 'Infection').""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Applied Rule 2 (ID: 8) to ensure the indication is in the singular form (input was already singular).""}]","[{""component"": ""Clostridioides difficile infection"", ""type"": ""Disease/Condition"", ""normalized_form"": ""Clostridioides Difficile Infection"", ""rule_applied"": ""Title Case Conversion""}]",1.0,1.0,0.98,1.0,0
327778,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy,AML,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,session_title,0.98,"The session title explicitly mentions 'Acute Myeloid Leukemias' and the abstract title refers to 'AML'. Following the rule to convert plural disease terms to singular form, 'Acute Myeloid Leukemias' is normalized to 'Acute Myeloid Leukemia'. The context confirms the study focuses on biomarkers and prognosis within this specific disease.","[{""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert plural disease terms like 'Leukemias' to the singular 'Leukemia'.""}, {""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case.""}]","[{""component"": ""Acute Myeloid Leukemias"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Singularization""}]",1.0,1.0,1.0,1.0,0
147554,Acute Lymphoblastic Leukemia - Clinical,Antibodies To Pegylated E. Coli Asparaginase Predict The Occurrence Of Hypersensitivity Reactions In High-Risk Patients Undergoing The Consolidation Phase Of The Aieop-Bfm All 2009 Protocol.,High-Risk;;Acute Lymphoblastic Leukemia,High-Risk Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,True,Session Title: Acute Lymphoblastic Leukemia - Clinical; Abstract Title: Antibodies To Pegylated E. Coli Asparaginase Predict The Occurrence Of Hypersensitivity Reactions In High-Risk Patients Undergoing The Consolidation Phase Of The Aieop-Bfm All 2009 Protocol.,0.98,"The session title explicitly mentions 'Acute Lymphoblastic Leukemia'. The abstract title supports this by referencing the 'Aieop-Bfm All 2009 Protocol', which is a treatment protocol for Acute Lymphoblastic Leukemia (ALL). 'High-Risk' is identified as a patient subgroup modifier rather than part of the core disease name in this context. The indication is formatted in Title Case and Singular form according to retrieved rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case formatting to the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Ensured Singular form (though input was already singular) and checked against exclusion rules.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Evaluated potential patient subgroup modifiers; 'High-Risk' (describing patients) was excluded to isolate the core indication.""}]","[{""component"": ""Acute Lymphoblastic Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Acute Lymphoblastic Leukemia"", ""rule_applied"": ""Title Case; Singular""}]",1.0,1.0,1.0,1.0,0
327789,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III","Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity",Mixed Phenotypic Acute Leukemia,Mixed Phenotypic Acute Leukemia,mixed phenotypic acute leukemia,True,abstract_title,0.95,"The abstract title explicitly identifies 'Mixed Phenotypic Acute Leukemia (MPAL)' as the specific disease entity being studied using multiomic single-cell sequencing. The session title 'Acute Myeloid Leukemias' is a broader category, but the abstract title provides the precise indication. The indication is normalized to lowercase.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""Standardize casing to lowercase for non-proper nouns and remove unnecessary surrounding text.""}, {""category"": ""Indication Extraction"", ""subcategories"": [""Priority""], ""reason"": ""Prioritize abstract title specificities over broader session headers.""}]","[{""component"": ""Mixed Phenotypic Acute Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""mixed phenotypic acute leukemia"", ""rule_applied"": ""Standardize Casing""}, {""component"": ""MPAL"", ""type"": ""Abbreviation"", ""normalized_form"": ""MPAL"", ""rule_applied"": ""Extraction (Parenthetical)""}]",0.98,1.0,0.99,1.0,0
376961,Acute myeloid leukemia - Clinical,Lifetime Clinical Outcomes Of Cpx-351 Versus 7+3 Modeled From The 5-Year Results Of A Randomized Phase 3 Trial For Older Adults With Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia,Older Adults;;Newly Diagnosed;;High-Risk;;Secondary;;Acute Myeloid Leukaemia,Elderly Newly Diagnosed High-Risk Secondary Acute Myeloid Leukaemia,Newly Diagnosed High-Risk Acute Myeloid Leukaemia;;Newly Diagnosed Secondary Acute Myeloid Leukaemia,True,Lifetime Clinical Outcomes Of Cpx-351 Versus 7+3 Modeled From The 5-Year Results Of A Randomized Phase 3 Trial For Older Adults With Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia,0.98,"The text identifies the target condition as 'Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia' in 'Older Adults'. 'Older Adults' is a demographic description and is excluded from the specific medical indication. The core disease is 'Acute Myeloid Leukaemia'. There are two distinct disease modifiers linked by 'Or': 'High-Risk' and 'Secondary'. The modifier 'Newly Diagnosed' applies to the disease context. Therefore, the indication is split into two distinct entities: 'Newly Diagnosed High-Risk Acute Myeloid Leukaemia' and 'Newly Diagnosed Secondary Acute Myeloid Leukaemia'. The spelling 'Leukaemia' is retained from the source text, and Title Case is applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""Applied Rule 7 for Title Case conversion and Rule 8 to ensure singular formatting.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Checked for specific patient subgroup modifiers like 'De Novo' or 'Associated'; none directly applied to the retained terms, but 'Older Adults' was excluded as a general demographic.""}]","[{""component"": ""Newly Diagnosed"", ""type"": ""Modifier"", ""normalized_form"": ""Newly Diagnosed"", ""rule_applied"": ""Title Case""}, {""component"": ""High-Risk"", ""type"": ""Modifier"", ""normalized_form"": ""High-Risk"", ""rule_applied"": ""Title Case""}, {""component"": ""Secondary"", ""type"": ""Modifier"", ""normalized_form"": ""Secondary"", ""rule_applied"": ""Title Case""}, {""component"": ""Acute Myeloid Leukaemia"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukaemia"", ""rule_applied"": ""Title Case""}, {""component"": ""Older Adults"", ""type"": ""Population"", ""normalized_form"": ""Excluded"", ""rule_applied"": ""Demographic Exclusion""}]",1.0,1.0,1.0,1.0,0
327823,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation,Mutated;;NPM1;;AML,NPM1-Mutated Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,session_title and abstract_title,0.98,"The session title explicitly mentions 'Acute Myeloid Leukemias', which was normalized to the singular form 'Acute Myeloid Leukemia' based on general formatting rules. The abstract title confirms the disease with the abbreviation 'AML' and specifies a patient subgroup (mutated NPM1) and procedure (Allogeneic Stem Cell Transplantation), but the core medical indication remains the primary disease entity.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case (Rule ID 7).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert plural disease terms ('Leukemias') to the singular form ('Leukemia') (Rule ID 8).""}]","[{""component"": ""Acute Myeloid Leukemias"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Singularization""}, {""component"": ""AML"", ""type"": ""Abbreviation"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Abbreviation Expansion""}, {""component"": ""Mutated NPM1"", ""type"": ""Biomarker"", ""normalized_form"": ""Mutated NPM1"", ""rule_applied"": ""Extraction (Contextual)""}]",1.0,1.0,1.0,1.0,0
311449,Abstracts: SLE - Treatment,Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Systemic lupus erythematosus,True,Abstract Title,0.98,The abstract title explicitly mentions 'Systemic Lupus Erythematosus' in the context of hospitalizations and flares treated by Hydroxychloroquine. This is the primary disease condition identified.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted with sentence case or standard dictionary casing (lowercase except proper nouns).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To validate the extracted text corresponds to a recognized medical condition.""}]","[{""component"": ""Systemic Lupus Erythematosus"", ""type"": ""Disease Name"", ""normalized_form"": ""Systemic lupus erythematosus"", ""rule_applied"": ""Casing and Normalization""}]",1.0,1.0,1.0,1.0,0
327859,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance,ALL,Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia,True,Session Title,0.98,"The indication was derived primarily from the session title which explicitly states 'Acute Lymphoblastic Leukemias'. The plural form was normalized to the singular 'Acute Lymphoblastic Leukemia' following standard medical terminology conventions. The abstract title confirms the context with 'UKALL' (United Kingdom Acute Lymphoblastic Leukaemia) and specific risk profiles, supporting the diagnosis of ALL.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""Pluralisation""], ""reason"": ""To ensure correct capitalization (Title Case) and grammatical number (Singular) for the disease name.""}, {""category"": ""Diseases"", ""subcategories"": [""Oncology""], ""reason"": ""To verify standard nomenclature for leukemia types.""}]","[{""component"": ""Acute Lymphoblastic Leukemias"", ""type"": ""Disease Name"", ""normalized_form"": ""Acute Lymphoblastic Leukemia"", ""rule_applied"": ""Normalize to singular form""}]",1.0,1.0,1.0,1.0,0
393400,Gynaecological Cancers,Tumor-Informed Ctdna Detection As A Predictive Marker For Postoperative Residual Disease In Epithelial Ovarian Cancer: A Feasibility Study,Epithelial Ovarian Cancer,Epithelial Ovarian Cancer,Epithelial Ovarian Cancer,True,Abstract Title,0.98,The abstract title explicitly specifies 'Epithelial Ovarian Cancer' as the disease context for the study. This is a specific medical indication compared to the broader 'Gynaecological Cancers' found in the session title. The extracted term follows the casing rules (Title Case) and singularization rules retrieved.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To apply Title Case formatting to the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form (though already singular in this case).""}]","[{""component"": ""Epithelial"", ""type"": ""Histology/Subtype"", ""normalized_form"": ""Epithelial"", ""rule_applied"": ""Title Case""}, {""component"": ""Ovarian"", ""type"": ""Anatomic Site"", ""normalized_form"": ""Ovarian"", ""rule_applied"": ""Title Case""}, {""component"": ""Cancer"", ""type"": ""Disease"", ""normalized_form"": ""Cancer"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
377049,Acute myeloid leukemia - Biology & Translational Research,"Therapeutic Potential And Strategies Of Pim447, A Pan-Pim Inhibitor, Targeting Refractory Myeloid Leukemia With Kit-Driven T(8/21)",Refractory;;Myeloid Leukemia,Refractory Myeloid Leukemia,Refractory Acute Myeloid Leukemia,True,abstract_title,0.95,"The abstract title specifies 'Refractory Myeloid Leukemia'. The session title 'Acute myeloid leukemia' confirms the specific type of leukemia. Therefore, 'Myeloid Leukemia' is normalized to 'Acute Myeloid Leukemia'. The patient subgroup 'Refractory' is preserved as it defines the specific therapeutic target population stated in the text. 'Kit-Driven T(8/21)' is considered a molecular subtype/biomarker and is typically treated as a specifier rather than the core indication name, though it validates the AML context.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To determine capitalization standards (Title Case) and handling of general disease terms.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Refractory/Relapsed""], ""reason"": ""To check if 'Refractory' status should be included in the primary indication string.""}, {""category"": ""Disease specific"", ""subcategories"": [""Hematology""], ""reason"": ""To validate the normalization of 'Myeloid Leukemia' to 'Acute Myeloid Leukemia'.""}]","[{""component"": ""Refractory"", ""type"": ""Patient Sub-Group"", ""normalized_form"": ""Refractory"", ""rule_applied"": ""Include patient status modifiers""}, {""component"": ""Myeloid Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Contextual normalization based on session title""}, {""component"": ""Kit-Driven T(8/21)"", ""type"": ""Biomarker/Mutation"", ""normalized_form"": ""KIT-driven t(8;21)"", ""rule_applied"": ""Biomarker extraction (excluded from main indication name)""}]",1.0,1.0,0.98,1.0,0
180442,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I","Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study",Adults;;Newly Diagnosed;;Acute Myeloid Leukemia,Adult Newly Diagnosed Acute Myeloid Leukemia,Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy,True,"Abstract Title: Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study",0.98,"The indication was extracted from the abstract title, specifically the phrase following 'Treatment of'. The phrase 'Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy' captures the target population, disease condition, diagnosis status, and fitness constraint. The text was normalized to Title Case per the retrieved casing rules, with prepositions 'with' and 'for' kept in lowercase.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case, capitalizing significant words while keeping conjunctions and prepositions lowercase.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To enforce the singular form of the disease name (Acute Myeloid Leukemia) instead of the plural form found in the session title.""}]","[{""component"": ""Adults"", ""type"": ""Population"", ""normalized_form"": ""Adults"", ""rule_applied"": ""Extraction of target demographic""}, {""component"": ""Newly Diagnosed"", ""type"": ""Status"", ""normalized_form"": ""Newly Diagnosed"", ""rule_applied"": ""Title Case normalization""}, {""component"": ""Acute Myeloid Leukemia"", ""type"": ""Condition"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Singular form enforcement""}, {""component"": ""Unfit for Intensive Therapy"", ""type"": ""Constraint"", ""normalized_form"": ""Unfit for intensive therapy"", ""rule_applied"": ""Preservation of clinical qualifier""}]",1.0,1.0,1.0,1.0,0
147689,Acute Myeloid Leukemia - Clinical,Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd,Aml,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,Abstract Title,0.95,"The indication was extracted from the abstract title '...In Aml Patients With Persistent Mrd'. 'Aml' was expanded to 'Acute Myeloid Leukemia'. The phrase 'Persistent Mrd' was evaluated under Patient Sub-Group rules. Rule 481 (Persistent) indicates that 'Persistent' should be excluded if it modifies a biomarker or status (MRD - Measurable Residual Disease) rather than the disease itself. Therefore, the core indication is retained as 'Acute Myeloid Leukemia' and formatted in Title Case per the Casing rule.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case to the finalized indication string as per Rule 7.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Used Rule 481 (Persistent) to analyze 'Persistent Mrd'. Since MRD represents a status/biomarker, the modifier 'Persistent' is excluded from the final indication.""}]","[{""component"": ""Aml"", ""type"": ""Disease Abbreviation"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Abbreviation Expansion""}, {""component"": ""Persistent Mrd"", ""type"": ""Patient Subgroup/Status"", ""normalized_form"": ""Persistent Measurable Residual Disease"", ""rule_applied"": ""Rule 481 (Exclusion)""}]",1.0,1.0,0.98,1.0,0
409842,Collagen IV Conundrums: Genetic Variants and Clinical Management,Do All Collagen Variants Cause Glomerular Disease?,,,Glomerular disease,True,abstract_title,0.95,"The abstract title explicitly questions the relationship between collagen variants and 'Glomerular Disease', identifying it as the primary clinical condition. The session title provides context (Collagen IV) but the indication itself is the disease entity.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the disease name is capitalized correctly (sentence case usually preferred for general conditions unless proper nouns) and stripped of surrounding whitespace.""}, {""category"": ""Disease Specific"", ""subcategories"": [""Renal""], ""reason"": ""To check for specific nomenclature regarding Collagen IV nephropathies versus general Glomerular disease.""}]","[{""component"": ""Glomerular Disease"", ""type"": ""Disease"", ""normalized_form"": ""Glomerular disease"", ""rule_applied"": ""Normalize to sentence case""}, {""component"": ""Collagen Variants"", ""type"": ""Etiology"", ""normalized_form"": ""Collagen variants"", ""rule_applied"": ""Contextual extraction""}]",1.0,1.0,0.98,1.0,0
377088,Infections in hematology (incl. supportive care/therapy),Clinical Characteristics Of Patients With Prolonged Viral Shedding Of Omicron Variant In Haematological Disease,Haematological Disease,Haematological Disease,Haematological Disease;;Omicron Variant,True,Clinical Characteristics Of Patients With Prolonged Viral Shedding Of Omicron Variant In Haematological Disease,0.95,"Extracted 'Haematological Disease' and 'Omicron Variant' as the key clinical indications. 'Haematological Disease' represents the underlying patient condition, and 'Omicron Variant' represents the specific infection (as context for viral shedding). 'Prolonged Viral Shedding' was identified as a clinical characteristic/outcome of the infection rather than a standalone disease indication. Applied Title Case formatting (Rule 7). The term 'In' suggests a co-occurrence of conditions rather than a single 'Associated' diagnosis, thus they are separated by ';;'. Kept singular forms as per standard rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case rule to formatting of 'Haematological Disease' and 'Omicron Variant'.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Used Singular rule logic; input terms were already singular or specific variants.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Analyzed context for patient sub-groups; 'Haematological Disease' defines the patient population.""}]","[{""component"": ""Haematological Disease"", ""type"": ""Condition"", ""normalized_form"": ""Haematological Disease"", ""rule_applied"": ""Title Case""}, {""component"": ""Omicron Variant"", ""type"": ""Infection/Virus"", ""normalized_form"": ""Omicron Variant"", ""rule_applied"": ""Title Case""}]",1.0,1.0,0.95,1.0,0
377121,Stem cell transplantation - Clinical,Single Nucleotide Polymorphisms In Patients With Endothelial Damage After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation,,,endothelial damage after allogeneic hematopoietic stem cell transplantation,True,Single Nucleotide Polymorphisms In Patients With Endothelial Damage After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation,0.92,The indication was extracted by identifying the specific medical condition ('Endothelial Damage') and the context ('After... Allogeneic Hematopoietic Stem Cell Transplantation'). The patient subgroup 'Pediatric' was removed in accordance with standard exclusions for indication naming unless specific to a pediatric-only disease definition. The phrase 'Single Nucleotide Polymorphisms In Patients With' was identified as the study subject/methodology and removed. The final output was normalized to lowercase.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Convert text to lowercase, preserving specific acronyms if applicable.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Exclude demographic descriptors (e.g., 'Pediatric', 'Adult') from the indication string.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Remove introductory phrases such as 'In Patients With' or 'Study of'.""}]","[{""component"": ""Single Nucleotide Polymorphisms In Patients With"", ""type"": ""Context/Noise"", ""normalized_form"": """", ""rule_applied"": ""Remove introductory context""}, {""component"": ""Endothelial Damage"", ""type"": ""Condition"", ""normalized_form"": ""endothelial damage"", ""rule_applied"": ""Lowercase""}, {""component"": ""Pediatric"", ""type"": ""Patient Sub-group"", ""normalized_form"": """", ""rule_applied"": ""Remove patient subgroup""}, {""component"": ""Allogeneic Hematopoietic Stem Cell Transplantation"", ""type"": ""Procedure"", ""normalized_form"": ""allogeneic hematopoietic stem cell transplantation"", ""rule_applied"": ""Lowercase""}]",1.0,1.0,0.95,1.0,0
311607,Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes,"UTI Biofilms, Amyloid, and Lupus Flares",,,UTI Biofilm;;Amyloid;;Lupus Flare,True,abstract_title,0.95,"The abstract title lists specific clinical conditions ('UTI Biofilms', 'Amyloid', 'Lupus Flares'). These were extracted and normalized. 'UTI' was preserved as a recognized abbreviation. Plural terms 'Biofilms' and 'Flares' were converted to singular 'Biofilm' and 'Flare' respectively, following the Singularity rule. The term 'Amyloid' was retained. All terms were formatted in Title Case and separated by ';;' as per the formatting rules for multiple indications.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To apply Title Case formatting to the extracted indications while preserving recognized abbreviations like UTI.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert plural disease terms (e.g., 'Biofilms', 'Flares') to their singular forms and handle multiple indications with standard delimiters.""}]","[{""component"": ""UTI Biofilms"", ""type"": ""Condition"", ""normalized_form"": ""UTI Biofilm"", ""rule_applied"": ""Singularization, Abbreviation Preservation""}, {""component"": ""Amyloid"", ""type"": ""Condition"", ""normalized_form"": ""Amyloid"", ""rule_applied"": ""Title Case""}, {""component"": ""Lupus Flares"", ""type"": ""Condition"", ""normalized_form"": ""Lupus Flare"", ""rule_applied"": ""Singularization, Title Case""}]",1.0,1.0,0.95,1.0,0
393583,Hepatocellular Carcinoma (Hcc),"Comparative Efficacy Of Systemic Sequential Regorafenib After Sorafenib Or Lenvatinib Treatment Failure For Advanced Hepatocellular Carcinoma: A Retrospective, Multi-Center, Real-World Study",Advanced;;Hepatocellular Carcinoma,Advanced Hepatocellular Carcinoma,Advanced Hepatocellular Carcinoma,True,abstract_title,0.98,"The abstract title explicitly identifies the condition being treated as 'Advanced Hepatocellular Carcinoma'. While the text mentions 'After Sorafenib Or Lenvatinib Treatment Failure', this describes the specific line of therapy/patient history for the drug's usage within the study, but the core medical indication is Advanced Hepatocellular Carcinoma. Standard formatting rules (Title Case, Singular) were applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine the correct capitalization format (Title Case) for the indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form where applicable.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Prior Lines of Therapy""], ""reason"": ""To check for specific rules regarding the inclusion of treatment history phrases in the indication string.""}]","[{""component"": ""Advanced"", ""type"": ""Stage/Severity"", ""normalized_form"": ""Advanced"", ""rule_applied"": ""Title Case""}, {""component"": ""Hepatocellular Carcinoma"", ""type"": ""Disease"", ""normalized_form"": ""Hepatocellular Carcinoma"", ""rule_applied"": ""Title Case; Singular""}]",1.0,1.0,1.0,1.0,0
393639,Investigational Immunotherapy,Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database,,,Pulmonary Adverse Event,True,abstract_title,0.95,"The text describes an analysis of 'Pulmonary Adverse Events' associated with a drug class. No specific therapeutic indication (e.g., specific cancer type) for the drugs is mentioned. Therefore, the condition being studied, 'Pulmonary Adverse Events', is extracted. Standard formatting rules were applied: the term was converted to singular form ('Events' to 'Event') and formatted in Title Case.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To enforce Title Case formatting for the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert the plural term 'Adverse Events' to the singular 'Adverse Event' as per the Singular rule.""}]","[{""component"": ""Pulmonary Adverse Events"", ""type"": ""Condition"", ""normalized_form"": ""Pulmonary Adverse Event"", ""rule_applied"": ""Singular""}, {""component"": ""Immune Checkpoint Inhibitors"", ""type"": ""Drug Class"", ""normalized_form"": ""Immune Checkpoint Inhibitors"", ""rule_applied"": ""None""}]",1.0,1.0,0.95,1.0,0
295345,Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?,Presentation by Expert,Chronic lymphocytic leukemia,Chronic Lymphocytic Leukemia,"Chronic Lymphocytic Leukemia (CLL), First-Line Therapy",True,Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?,0.98,The session title explicitly mentions the condition 'Chronic lymphocytic leukemia (CLL)' and the treatment setting 'first-line therapy'. The abstract title is generic and not useful. The indication is formatted to Title Case and includes the specific line of therapy identified.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Indication text must be in Title Case.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Line of therapy""], ""reason"": ""Normalize 'first-line' to 'First-Line' and include 'Therapy' or 'Treatment' if specified.""}]","[{""component"": ""Chronic lymphocytic leukemia (CLL)"", ""type"": ""Condition"", ""normalized_form"": ""Chronic Lymphocytic Leukemia (CLL)"", ""rule_applied"": ""Preserve abbreviation in parentheses; apply Title Case""}, {""component"": ""first-line therapy"", ""type"": ""Treatment Line"", ""normalized_form"": ""First-Line Therapy"", ""rule_applied"": ""Normalize line of therapy casing""}]",1.0,1.0,1.0,1.0,0
393652,Melanoma And Other Skin Tumours,Adjuvant Treatment With Anti-Pd-1 In Acral Melanoma Patients: A Nationwide Study,Acral Melanoma,Acral Melanoma,Acral Melanoma,True,Abstract Title,0.95,"The abstract title specifies 'Acral Melanoma Patients' as the target population. 'Adjuvant Treatment With Anti-Pd-1' represents the intervention and setting, which are typically excluded from the core indication unless defining a specific line of therapy essential to the indication's identity. The session title 'Melanoma And Other Skin Tumours' provides the broader context but is less specific. The term 'Patients' is removed per standard cleaning rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To apply standard casing rules (Title Case) and remove extra whitespace.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General"", ""Suffix Removal""], ""reason"": ""To identify and remove terms like 'Patients' or 'Subjects' from the disease string.""}, {""category"": ""Disease / Condition"", ""subcategories"": [""General""], ""reason"": ""To extract the primary disease entity from the context.""}]","[{""component"": ""Acral Melanoma"", ""type"": ""Disease"", ""normalized_form"": ""Acral Melanoma"", ""rule_applied"": ""Extract Disease Entity""}, {""component"": ""Patients"", ""type"": ""Population Term"", ""normalized_form"": """", ""rule_applied"": ""Remove Population Suffix""}, {""component"": ""Adjuvant Treatment"", ""type"": ""Treatment Setting"", ""normalized_form"": """", ""rule_applied"": ""Exclude Intervention/Setting""}]",1.0,1.0,1.0,1.0,0
344512,"New Insights into Cancer Initiation, Evolution, Therapy and Survivorship through Big Data Analysis",Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss,cancer,Cancer ,Cancer,True,Abstract Title,0.95,"The text discusses 'cancer genome evolution' and 'cancer initiation'. The primary disease entity identified is 'cancer'. Per the singularization and title casing rules, 'cancer' is formatted as 'Cancer'. 'Sporadic p53 loss' is a molecular mechanism/characteristic associated with the cancer but 'Cancer' is the broad indication.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form.""}]","[{""component"": ""cancer"", ""type"": ""Disease"", ""normalized_form"": ""Cancer"", ""rule_applied"": ""Singular; Title Case""}]",1.0,1.0,1.0,1.0,0
295375,"Gilead and Kite Oncology - Redefining the Lines of TNBC, Real-world management: improving survival for patients with metastatic TNBC",TNBC today: How can we increase survival for a very heterogenous and aggressive disease?,TNBC ,Triple-Negative Breast Cancer,Metastatic triple-negative breast cancer,True,session_title,0.98,"The indication was extracted from the session title context 'patients with metastatic TNBC'. The abbreviation TNBC was expanded to Triple-negative breast cancer, and the modifier 'Metastatic' was retained to accurately reflect the disease stage specified.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Apply sentence case to the generated indication.""}, {""category"": ""Disease / Condition"", ""subcategories"": [""Abbreviation""], ""reason"": ""Expand common medical abbreviations (TNBC to Triple-negative breast cancer).""}]","[{""component"": ""metastatic"", ""type"": ""stage"", ""normalized_form"": ""Metastatic"", ""rule_applied"": ""Keep specific disease stage modifiers""}, {""component"": ""TNBC"", ""type"": ""disease"", ""normalized_form"": ""triple-negative breast cancer"", ""rule_applied"": ""Expand standard oncology abbreviations""}]",1.0,1.0,1.0,1.0,0
213477,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Endoscopic Injection Of The Bladder Neck Using Dextranomer Hyaluronate (Dx/Ha) In The Pediatric Patient: Results Of A Single Center Analysis With Long Term Follow Up,Neurogenic Bladder;;Pediatric,Pediatric Neurogenic Bladder,Neurogenic Bladder,True,Session Title,0.9,"The Session Title explicitly categorizes the presentation under 'Neurogenic Bladder', which provides the specific medical condition context for the procedure described in the Abstract Title ('Endoscopic Injection Of The Bladder Neck Using Dextranomer Hyaluronate'). While the abstract title specifies the intervention and the 'Pediatric Patient' population, 'Neurogenic Bladder' is the distinct medical indication treated. The indication is formatted in Title Case and Singular form according to the retrieved rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Rule ID 7: Convert finalized medical-indication phrase to Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Rule ID 8: Convert to Singular form.""}]","[{""component"": ""Neurogenic Bladder"", ""type"": ""Condition"", ""normalized_form"": ""Neurogenic Bladder"", ""rule_applied"": ""Title Case""}, {""component"": ""Pediatric Patient"", ""type"": ""Population"", ""normalized_form"": ""Pediatric Patient"", ""rule_applied"": ""Excluded from Indication (Population)""}, {""component"": ""Endoscopic Injection Of The Bladder Neck"", ""type"": ""Procedure"", ""normalized_form"": ""Endoscopic Injection Of The Bladder Neck"", ""rule_applied"": ""Context for Indication""}]",1.0,1.0,0.95,1.0,0
262670,Myeloproliferative neoplasms - Clinical,Higher Estimated Plasma Volume Status Is Associated With Increased Thrombotic Risk And Impaired Survival In Patients With Primary Myelofibrosis,Primary;;Myelofibrosis,Primary Myelofibrosis,primary myelofibrosis,True,Abstract title,0.98,The abstract title explicitly identifies the patient population as 'Patients With Primary Myelofibrosis'. This is more specific than the session title 'Myeloproliferative neoplasms'. The indication is extracted and formatted to lower case following standard indication extraction conventions.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the indication is formatted in lower case and follows general extraction guidelines.""}, {""category"": ""Disease specific"", ""subcategories"": [""General""], ""reason"": ""To correctly identify the specific type of myelofibrosis mentioned.""}]","[{""component"": ""primary"", ""type"": ""modifier"", ""normalized_form"": ""primary"", ""rule_applied"": ""Include descriptive modifiers that define the specific disease entity.""}, {""component"": ""myelofibrosis"", ""type"": ""disease_entity"", ""normalized_form"": ""myelofibrosis"", ""rule_applied"": ""Extract the core disease name.""}]",1.0,1.0,1.0,1.0,0
262704,Platelet disorders,Low Serum Bdnf Levels Are Associated With Lower Platelets' Cd62P Reactivity And Increased Bleeding Tendency In Patients With Gaucher Disease,Gaucher Disease,Gaucher Disease,Gaucher disease,True,Abstract Title,0.98,"The abstract title explicitly identifies the patient population as 'Patients With Gaucher Disease'. While the session title 'Platelet disorders' provides context, the specific medical condition being studied is Gaucher disease, making it the primary indication. The phrase 'Patients With' was removed as per standard extraction rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To determine correct capitalization (Gaucher disease vs Gaucher Disease) and general extraction cleanup.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""To identify and remove non-indicative prefixes like 'Patients With'.""}]","[{""component"": ""Gaucher Disease"", ""type"": ""Disease"", ""normalized_form"": ""Gaucher disease"", ""rule_applied"": ""Eponym capitalization rule (Gaucher) and lowercasing common noun (disease)""}]",1.0,1.0,1.0,1.0,0
393855,"Nsclc, Metastatic",First-Line Osimertinib In Patients With Egfr Mutated Lung Cancer With Uncommon Mutations (Ocelot Study - Interim Analysis),Egfr;;Mutated;;Lung Cancer,EGFR-Mutated Lung Cancer,First-line treatment of metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations,True,Abstract Title and Session Title,0.95,"The indication was constructed by combining the disease stage 'Metastatic' and type 'Nsclc' from the session title with the therapy line 'First-Line' and patient subgroup 'Egfr Mutated... Uncommon Mutations' from the abstract title. 'Nsclc' was expanded to 'non-small cell lung cancer' for clarity, and 'Egfr' was normalized to 'EGFR' per standard gene nomenclature. The phrase 'In Patients With' was converted to standard indication format 'treatment of...'.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the final output follows sentence case and standard grammar (e.g., capitalizing the first letter).""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Biomarker"", ""Gene Nomenclature""], ""reason"": ""To enforce correct capitalization of gene symbols (e.g., changing 'Egfr' to 'EGFR').""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Line of Therapy""], ""reason"": ""To standardize the formatting of therapy lines (e.g., 'First-Line' to 'First-line').""}]","[{""component"": ""First-Line"", ""type"": ""Line of Therapy"", ""normalized_form"": ""First-line"", ""rule_applied"": ""Standardize Line of Therapy""}, {""component"": ""Nsclc"", ""type"": ""Disease"", ""normalized_form"": ""Non-small cell lung cancer (NSCLC)"", ""rule_applied"": ""Expand Abbreviations""}, {""component"": ""Metastatic"", ""type"": ""Stage"", ""normalized_form"": ""Metastatic"", ""rule_applied"": ""Preserve Disease Stage""}, {""component"": ""Egfr Mutated"", ""type"": ""Biomarker"", ""normalized_form"": ""EGFR mutations"", ""rule_applied"": ""Gene Symbol Capitalization""}, {""component"": ""Uncommon Mutations"", ""type"": ""Biomarker Detail"", ""normalized_form"": ""uncommon mutations"", ""rule_applied"": ""Lowercase descriptive terms""}]",1.0,1.0,0.98,1.0,0
344703,Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED),cancer,Cancer,Multi-cancer early detection,True,abstract_title,0.95,"The abstract title describes a platform developed for 'multi-cancer early detection'. Terms indicating the methodology ('Development of...', 'platform for...') were removed to isolate the clinical indication. The abbreviation (MCED) was removed in favor of the full term, and sentence casing was applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Enforce sentence case for the final indication string.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Remove investigational context words (e.g., 'Development of', 'platform') to isolate the disease or condition.""}, {""category"": ""Formatting"", ""subcategories"": [""Abbreviations""], ""reason"": ""Prefer full term over abbreviations; removed '(MCED)'.""}]","[{""component"": ""multi-cancer"", ""type"": ""Target Disease Group"", ""normalized_form"": ""Multi-cancer"", ""rule_applied"": ""Capitalization correction""}, {""component"": ""early detection"", ""type"": ""Clinical Objective"", ""normalized_form"": ""early detection"", ""rule_applied"": ""Exact extraction""}]",1.0,1.0,0.98,1.0,0
393888,"Nsclc, Metastatic",Updated Patient-Reported Outcomes From The Crown Study: Analyses In First-Line Alk+ Patients With (W) And Without (W/O) Baseline Brain Metastases (Bms) And W Or W/O Central Nervous System Adverse Events (Cns Aes),First-Line;;Alk+;;Metastatic;;Nsclc,First-Line ALK-Postive Metastatic Non-Small Cell Lung Cancer,ALK-positive metastatic non-small cell lung cancer (NSCLC),True,abstract_title,0.95,"Extracted 'Nsclc' as the primary disease and normalized to 'non-small cell lung cancer (NSCLC)'. Identified 'Metastatic' from the session title as the stage. Identified 'Alk+' from the abstract title as the specific biomarker 'ALK-positive'. The 'First-Line' mention confirms the treatment setting but the core medical indication is defined by the disease, stage, and biomarker.","[{""category"": ""Common Check points"", ""subcategories"": [""Acronyms"", ""Casing""], ""reason"": ""To ensure 'Nsclc' is expanded to 'non-small cell lung cancer (NSCLC)' and 'Alk' is uppercased to 'ALK'.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Biomarker""], ""reason"": ""To correctly format 'Alk+' as 'ALK-positive'.""}, {""category"": ""Disease/Condition"", ""subcategories"": [""Normalization""], ""reason"": ""To standardise 'Nsclc, Metastatic' into the phrase 'Metastatic non-small cell lung cancer'.""}]","[{""component"": ""Nsclc"", ""type"": ""Disease"", ""normalized_form"": ""non-small cell lung cancer (NSCLC)"", ""rule_applied"": ""Acronym Expansion""}, {""component"": ""Metastatic"", ""type"": ""Stage"", ""normalized_form"": ""Metastatic"", ""rule_applied"": ""Standard Casing""}, {""component"": ""Alk+"", ""type"": ""Biomarker"", ""normalized_form"": ""ALK-positive"", ""rule_applied"": ""Biomarker Formatting""}]",1.0,1.0,1.0,1.0,0
410286,"Kidney Transplantation: Biomarkers, New and Old",Differential cfDNA Methylation in Kidney Allograft Rejection,,,Kidney Allograft Rejection,True,abstract_title,0.98,"The abstract title explicitly identifies 'Kidney Allograft Rejection' as the condition where differential cfDNA methylation is being studied (indicated by the preposition 'in'). This is a specific pathological condition, whereas 'Kidney Transplantation' in the session title is the broader procedural context. The indication is extracted directly and formatted according to standard rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case to the extracted indication (Rule ID 7).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Verified the indication is in Singular form (Rule ID 8).""}]","[{""component"": ""Kidney"", ""type"": ""Anatomy"", ""normalized_form"": ""Kidney"", ""rule_applied"": ""Title Case""}, {""component"": ""Allograft Rejection"", ""type"": ""Condition"", ""normalized_form"": ""Allograft Rejection"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
410288,"Kidney Transplantation: Biomarkers, New and Old",Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection,,,Kidney transplant T cell-mediated rejection,True,abstract_title,0.95,"The abstract title explicitly mentions 'Kidney Transplant T Cell-Mediated Rejection', which represents the specific pathological condition being studied. This is more specific than the session title 'Kidney Transplantation'. The casing was normalized to sentence case, keeping standard capitalization for 'T cell'.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the indication follows sentence case and does not end with punctuation.""}, {""category"": ""Indication"", ""subcategories"": [""Specificity""], ""reason"": ""To select the most specific disease or condition available in the source text.""}]","[{""component"": ""Kidney transplant"", ""type"": ""Context/Procedure"", ""normalized_form"": ""Kidney transplant"", ""rule_applied"": ""Sentence case normalization""}, {""component"": ""T Cell-Mediated Rejection"", ""type"": ""Condition/Disease"", ""normalized_form"": ""T cell-mediated rejection"", ""rule_applied"": ""Preserve T cell capitalization, lowercase remainder""}]",1.0,1.0,1.0,1.0,0
393942,"Nsclc, Metastatic",Recurrence Of Infusion-Related Reaction (Irrs) Associated To Avimantamab,Nsclc;;Metastatic,Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,True,Session Title,0.98,"The session title 'Nsclc, Metastatic' provides a clear disease entity and stage. 'Nsclc' is a standard abbreviation for Non-Small Cell Lung Cancer. 'Metastatic' specifies the stage. The abstract title refers to an adverse event (Infusion-Related Reaction) and the drug name, verifying the context but not providing the indication itself. The abbreviation was expanded and the stage placed as a pre-modifier per standard medical nomenclature.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the output follows title casing standards and general formatting rules.""}, {""category"": ""Disease/Condition"", ""subcategories"": [""Abbreviation"", ""Structure""], ""reason"": ""To handle the expansion of 'Nsclc' to 'Non-Small Cell Lung Cancer' and determine the correct word order for the stage.""}]","[{""component"": ""Nsclc"", ""type"": ""Disease"", ""normalized_form"": ""Non-Small Cell Lung Cancer"", ""rule_applied"": ""Abbreviation Expansion""}, {""component"": ""Metastatic"", ""type"": ""Stage/Subtype"", ""normalized_form"": ""Metastatic"", ""rule_applied"": ""Standardization""}]",1.0,1.0,1.0,1.0,0
410383,Kidney Transplantation: New Translational Insights,Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database,,,Kidney transplantation,True,abstract_title,0.95,"The abstract title specifies the study population as 'Kidney Transplant Recipients'. Following standard extraction protocols, the indication is normalized to the underlying procedure 'Kidney transplantation'. The session title confirms the context.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the generated indication follows sentence case conventions.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Recipients""], ""reason"": ""To map 'Recipients' terminology to the primary procedure or condition.""}]","[{""component"": ""Kidney Transplant Recipients"", ""type"": ""Population"", ""normalized_form"": ""Kidney transplantation"", ""rule_applied"": ""Map Recipient to Procedure""}]",1.0,1.0,0.98,1.0,0
230183,Breast Cancer-Metastatic,Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.,hyperglycemia ,Hyperglycemia ,Metastatic breast cancer,True,session_title,0.95,"The session title clearly identifies the primary disease condition (Breast Cancer) and its stage (Metastatic). The abstract title focuses on the management of an adverse event (hyperglycemia) resulting from treatment, but the underlying medical indication for the patient population is Metastatic breast cancer.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine the correct capitalization for the extracted indication.""}, {""category"": ""Indication Structure"", ""subcategories"": [""Ordering""], ""reason"": ""To ensure the stage 'Metastatic' correctly modifies the disease 'breast cancer'.""}]","[{""component"": ""Metastatic"", ""type"": ""Stage/Qualifier"", ""normalized_form"": ""metastatic"", ""rule_applied"": ""Standardize stage terminology""}, {""component"": ""Breast Cancer"", ""type"": ""Disease Name"", ""normalized_form"": ""breast cancer"", ""rule_applied"": ""Lowercase common disease names""}]",1.0,1.0,0.98,1.0,0
181043,Health Services Research-Non-Malignant Conditions: Poster I,Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need,,,Non-Malignant Condition,True,Session Title,0.85,"The session title explicitly categorizes the content under 'Non-Malignant Conditions'. While the abstract title refers to a 'Hematology Oncology Fellowship Program', this describes a medical specialty and educational context rather than a specific patient pathology. Therefore, the broader disease category from the session title is extracted. The term is singularized and title-cased according to the rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case to the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Converted plural 'Conditions' to singular 'Condition' based on singularization rules.""}]","[{""component"": ""Non-Malignant Conditions"", ""type"": ""Disease Category"", ""normalized_form"": ""Non-Malignant Condition"", ""rule_applied"": ""Singularization""}]",1.0,1.0,0.9,1.0,0
148309,Myeloproliferative Neoplasms - Clinical,Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis,Primary;;Myelofibrosis,Primary Myelofibrosis,Primary Myelofibrosis,True,abstract_title,0.99,"The specific disease entity 'Primary Myelofibrosis' is identified in the abstract title. The session title 'Myeloproliferative Neoplasms' represents a broader disease category, but the abstract specifically studies a predictor within Primary Myelofibrosis. In accordance with the retrieved 'Casing' rule (Rule ID 7), the indication is formatted in Title Case.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in the required Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form.""}]","[{""component"": ""Primary Myelofibrosis"", ""type"": ""Disease"", ""normalized_form"": ""Primary Myelofibrosis"", ""rule_applied"": ""Title Case conversion per Rule ID 7""}]",1.0,1.0,1.0,1.0,0
263003,Acute myeloid leukemia - Clinical,Utility Of Flt3 Inhibitors In Patients With Acute Myeloid Leukemia (Aml) And T(6;9)(P22;Q34),Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia (AML) with t(6;9)(p22;q34),True,Utility Of Flt3 Inhibitors In Patients With Acute Myeloid Leukemia (Aml) And T(6;9)(P22;Q34),0.98,The abstract title explicitly specifies the patient population as those with 'Acute Myeloid Leukemia (Aml)' and the specific cytogenetic abnormality 'T(6;9)(P22;Q34)'. The indication is constructed by combining the disease name and the genetic mutation. 'Aml' is normalized to 'AML' and the translocation notation is corrected to standard cytogenetic format 't(6;9)(p22;q34)' for clinical accuracy.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case to the disease name 'Acute Myeloid Leukemia' and kept the preposition 'with' in lower case, following the retrieved casing rule.""}, {""category"": ""Common Check points"", ""subcategories"": [""Abbreviations""], ""reason"": ""Normalized 'Aml' to 'AML' as a recognized medical abbreviation.""}]","[{""component"": ""Acute Myeloid Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Title Case""}, {""component"": ""Aml"", ""type"": ""Abbreviation"", ""normalized_form"": ""AML"", ""rule_applied"": ""Abbreviation Normalization""}, {""component"": ""T(6;9)(P22;Q34)"", ""type"": ""Genetic Mutation"", ""normalized_form"": ""t(6;9)(p22;q34)"", ""rule_applied"": ""Standard Cytogenetic Notation""}]",1.0,1.0,1.0,1.0,0
410466,Acute Kidney Injury,AKI and Spontaneous Rupture of the Urinary Collecting System,AKI,Acute Kidney Injury,Acute kidney injury and spontaneous rupture of the urinary collecting system,True,abstract_title,0.98,"The indication was extracted from the abstract title, which provides a more specific composite condition than the session title. The abbreviation 'AKI' was expanded to 'Acute kidney injury', and the entire phrase was formatted in sentence case according to standard indication rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the indication follows sentence case formatting and standard grammar.""}, {""category"": ""Abbreviation"", ""subcategories"": [""General""], ""reason"": ""To identify and expand the medical abbreviation 'AKI'.""}]","[{""component"": ""AKI"", ""type"": ""Abbreviation"", ""normalized_form"": ""Acute kidney injury"", ""rule_applied"": ""Expand abbreviations""}, {""component"": ""Spontaneous Rupture of the Urinary Collecting System"", ""type"": ""Medical Condition"", ""normalized_form"": ""spontaneous rupture of the urinary collecting system"", ""rule_applied"": ""Sentence casing""}]",1.0,1.0,1.0,1.0,0
181105,Outcomes Research-Non-Malignant Conditions: Poster I,Vaso-Occlusive Events in Pediatric Sickle Cell Disease: Quantifying Social Disadvantage and Its Impact on Hospitalizations,Pediatric;;Sickle Cell Disease,Pediatric Sickle Cell Disease,Pediatric Sickle Cell Disease,True,Vaso-Occlusive Events in Pediatric Sickle Cell Disease: Quantifying Social Disadvantage and Its Impact on Hospitalizations,0.95,"The text follows the pattern 'Condition X in Disease Y' ('Vaso-Occlusive Events in Pediatric Sickle Cell Disease'). Based on standard medical indication extraction guidelines and the provided rules, the primary disease 'Sickle Cell Disease' modified by the specific patient subgroup 'Pediatric' is extracted. 'Vaso-Occlusive Events' describes the specific complication or outcome being studied within this indication, rather than the indication itself, similar to the exclusion of symptoms or events in the 'Singular' rule examples (e.g., 'Surgeon fatigue in...'). The phrase is formatted in Title Case as per the 'Casing' rule.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Rule requires converting the finalized indication to Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Rule requires singularization of terms, though 'Sickle Cell Disease' is already singular. The logic of extracting the disease from 'X in Y' patterns is inferred from examples.""}]","[{""component"": ""Pediatric Sickle Cell Disease"", ""type"": ""Disease/Condition"", ""normalized_form"": ""Pediatric Sickle Cell Disease"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
164735,The Interplay Between COVID and other Infections,Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19,,,COVID-19,True,Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19,0.98,"Identified 'COVID-19' as the primary medical condition addressed by the intervention (masking and eye protection). The term is specific and clinically standard. While 'Bloodborne Pathogen Splash Exposures' is mentioned, it serves as the outcome measure rather than the indication for the intervention.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication follows Title Case formatting (Rule ID 7).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To check for singularization requirements, though 'COVID-19' is already singular (Rule ID 8).""}]","[{""component"": ""COVID-19"", ""type"": ""Disease"", ""normalized_form"": ""COVID-19"", ""rule_applied"": ""Standard Abbreviation Preservation""}]",1.0,1.0,1.0,1.0,0
312263,Moving on Up: Changing How We Define Early Knee OA and Get People Moving,Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field,Osteoarthritis ,Osteoarthritis ,Knee Osteoarthritis,True,"session_title: Moving on Up: Changing How We Define Early Knee OA and Get People Moving
abstract_title: Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field",0.95,"The input text contains specific mentions of 'Knee OA' and 'Osteoarthritis Patients'. The abbreviation 'OA' is resolved to 'Osteoarthritis' based on the explicit usage in the abstract title. The term 'Patients' is excluded as it refers to the population rather than the condition itself. 'Knee Osteoarthritis' captures the specific anatomical site and condition mentioned in the session title, which defines the primary scope. Standard Title Case formatting is applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To enforce Title Case formatting for the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To handle singular/plural forms and ensure standard disease naming conventions.""}]","[{""component"": ""Knee"", ""type"": ""Anatomic Site"", ""normalized_form"": ""Knee"", ""rule_applied"": ""N/A""}, {""component"": ""OA"", ""type"": ""Abbreviation"", ""normalized_form"": ""Osteoarthritis"", ""rule_applied"": ""Expansion based on context""}, {""component"": ""Osteoarthritis"", ""type"": ""Disease/Condition"", ""normalized_form"": ""Osteoarthritis"", ""rule_applied"": ""Singular Rule (Implicit)""}]",1.0,1.0,1.0,1.0,0
213982,MP36: Renal Transplantation & Vascular Surgery,The effect of renal transplantation on erectile functions in patients with end-stage renal disease.,end-stage;;renal disease,End-Stage Renal Disease,End-Stage Renal Disease,True,abstract_title,0.98,The abstract title explicitly identifies the patient population as 'patients with end-stage renal disease' who are undergoing the intervention (renal transplantation).,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine the correct capitalization format for the indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To check for singular/plural formatting rules.""}]","[{""component"": ""End-Stage"", ""type"": ""Stage/Severity"", ""normalized_form"": ""End-Stage"", ""rule_applied"": ""Title Case""}, {""component"": ""Renal"", ""type"": ""Anatomical Site"", ""normalized_form"": ""Renal"", ""rule_applied"": ""Title Case""}, {""component"": ""Disease"", ""type"": ""Condition"", ""normalized_form"": ""Disease"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
295920,Oligometastatic disease and oligoprogression in breast cancer,Systemic therapeutic options,Oligometastatic disease;;breast cancer,Oligometastatic Disease;;Breast Cancer,Oligometastatic breast cancer,True,session_title,0.95,The session title explicitly identifies 'breast cancer' as the primary disease and 'Oligometastatic disease' as the specific state. 'Oligoprogression' is a related clinical state often subsumed under the metastatic classification for high-level indication extraction.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the indication follows standard capitalization (Sentence case) and general formatting rules.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Disease Stage""], ""reason"": ""To correctly map 'Oligometastatic disease' as a specific stage/modifier of the primary cancer.""}]","[{""component"": ""breast cancer"", ""type"": ""Disease Entity"", ""normalized_form"": ""breast cancer"", ""rule_applied"": ""Extract primary disease entity""}, {""component"": ""Oligometastatic disease"", ""type"": ""Disease State"", ""normalized_form"": ""Oligometastatic"", ""rule_applied"": ""Map disease state/stage to modifier""}]",1.0,1.0,0.98,1.0,0
410619,"Fluid, Electrolytes, and Acid-Base Disorders",A Rare Case of Zonisamide-Induced Distal Renal Tubular Acidosis (RTA),Distal Renal Tubular Acidosis,Distal Renal Tubular Acidosis,Distal renal tubular acidosis,True,Abstract Title,0.95,"The indication was extracted from the abstract title. The phrase 'A Rare Case of' was identified as a noise pattern and removed. 'Zonisamide-Induced' describes the etiology, but the core clinical entity is 'Distal renal tubular acidosis'. The acronym '(RTA)' was removed to standardize on the full term.","[{""category"": ""Common Check points"", ""subcategories"": [""Noise Words"", ""Casing""], ""reason"": ""To remove non-clinical introductory phrases and standardize capitalization.""}, {""category"": ""Acronyms / Abbreviations"", ""subcategories"": [""General""], ""reason"": ""To prioritize the full expansion of the medical term over the abbreviation.""}]","[{""component"": ""A Rare Case of"", ""type"": ""Noise"", ""normalized_form"": ""N/A"", ""rule_applied"": ""Remove introductory noise""}, {""component"": ""Zonisamide-Induced"", ""type"": ""Etiology"", ""normalized_form"": ""Zonisamide"", ""rule_applied"": ""Exclude etiology from indication name""}, {""component"": ""Distal Renal Tubular Acidosis"", ""type"": ""Disease"", ""normalized_form"": ""Distal renal tubular acidosis"", ""rule_applied"": ""Standardize to sentence case""}, {""component"": ""(RTA)"", ""type"": ""Abbreviation"", ""normalized_form"": ""N/A"", ""rule_applied"": ""Remove abbreviation in favor of full term""}]",1.0,0.98,1.0,1.0,0
410621,"Fluid, Electrolytes, and Acid-Base Disorders",Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia,Severe;;Hyponatremia,Severe Hyponatremia,Severe Hyponatremia,True,abstract_title,0.98,"The abstract title identifies the specific medical condition ('Severe Hyponatremia') associated with the drug usage, which is more specific than the broad category in the session title. The etiology 'Trimethoprim-Sulfamethoxazole-Associated' was excluded to focus on the clinical condition.","[{""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To identify extraction boundaries for drug-associated conditions.""}, {""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication follows the standard Title Case format.""}]","[{""component"": ""Severe"", ""type"": ""Severity Modifier"", ""normalized_form"": ""Severe"", ""rule_applied"": ""Include relevant severity modifiers""}, {""component"": ""Hyponatremia"", ""type"": ""Condition"", ""normalized_form"": ""Hyponatremia"", ""rule_applied"": ""Extract primary clinical entity""}]",1.0,1.0,0.99,1.0,0
148549,Transfusion Medicine,Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain,,,Red Blood Cell Autoantibodies,True,Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain,0.95,"The study primarily evaluates patients with 'Red Blood Cell Autoantibodies'. 'Thrombotic Risk' is an associated factor/outcome being analyzed in this specific patient population. The indication is extracted directly from the title and formatted to Title Case. The plural form is retained as 'autoantibodies' refers to specific biological entities (similar to cells or genes) rather than a disease process like 'tumors' or 'cancers', falling under the exception for non-disease plurals.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication follows standard Title Case formatting.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To determine whether to singularize the term 'Autoantibodies'. Applied exception for non-disease plurals (biomarkers/entities).""}]","[{""component"": ""Red Blood Cell Autoantibodies"", ""type"": ""Condition/Biomarker"", ""normalized_form"": ""Red Blood Cell Autoantibodies"", ""rule_applied"": ""Extraction of primary noun phrase; Title Case; Plural retention (biomarker exception)""}, {""component"": ""Thrombotic Risk"", ""type"": ""Associated Risk"", ""normalized_form"": ""Thrombotic Risk"", ""rule_applied"": ""Identified as secondary outcome/association""}]",1.0,1.0,0.95,1.0,0
148578,Acute Lymphoblastic Leukemia - Clinical,L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia,Children;;Acute Pancreatitis;;Acute Lymphoblastic Leukemia,Childhood Acute Pancreatitis;;Acute Lymphoblastic Leukemia,Acute lymphoblastic leukemia,True,abstract_title,0.98,"The text identifies 'Acute Lymphoblastic Leukemia' as the underlying condition being treated with L-Asparaginase. While 'Acute Pancreatitis' is mentioned, it is identified as an associated adverse event ('L-Asparaginase Associated...'), not the indication. The patient subgroup 'Children' is present but the core indication is the disease itself.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To apply sentence casing rules to the extracted disease name.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Pediatric""], ""reason"": ""To determine if the pediatric population qualifier should be part of the primary indication string.""}, {""category"": ""Disease/Condition"", ""subcategories"": [""Oncology""], ""reason"": ""To validate the standard naming convention for leukemia types.""}]","[{""component"": ""Acute Lymphoblastic Leukemia"", ""type"": ""Disease"", ""normalized_form"": ""Acute lymphoblastic leukemia"", ""rule_applied"": ""Standardize to Sentence Case""}, {""component"": ""Children"", ""type"": ""Patient Population"", ""normalized_form"": ""Pediatric"", ""rule_applied"": ""Population Context Extraction""}, {""component"": ""L-Asparaginase Associated Acute Pancreatitis"", ""type"": ""Adverse Event"", ""normalized_form"": ""Acute pancreatitis"", ""rule_applied"": ""Exclusion of Adverse Events""}]",1.0,1.0,0.95,1.0,0
214129,MP45: Prostate Cancer: Markers,MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis,Prostate Cancer,Prostate Cancer,Prostate Cancer,True,"session_title: MP45: Prostate Cancer: Markers
abstract_title: MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis",0.95,"The session title clearly identifies 'Prostate Cancer' as the main condition. The abstract title discusses biomarkers in patients with 'low-risk disease' (referring to prostate cancer) and 'high-risk pathology'. The core disease entity is Prostate Cancer. Following the 'Title case' and 'Singular' rules, the output is formatted as 'Prostate Cancer'. Modifiers like 'high-risk' or 'low-risk' describe patient subgroups or disease characteristics in this context rather than a distinct disease entity nomenclature required for the indication output.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case formatting to the indication 'Prostate Cancer'.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Ensured the indication is in Singular form (though 'Cancer' was already singular).""}]","[{""component"": ""Prostate Cancer"", ""type"": ""Disease"", ""normalized_form"": ""Prostate Cancer"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
394376,Renal Cancer,Adjuvant Everolimus (Eve) In Patients (Pts) With Completely Resected Very High-Risk Renal Cell Cancer (Rcc) And Clear Cell Histology: Results From The Phase Iii Swog S0931 (Everest) Trial,Resected;;Very High-Risk;;Renal Cell Cancer,Resected Very High-Risk Renal Cell Cancer,Completely Resected Very High-Risk Renal Cell Carcinoma with Clear Cell Histology,True,abstract_title,0.92,Extracted the specific disease state and patient population from the abstract title. Mapped 'Renal Cell Cancer' to 'Renal Cell Carcinoma' and 'Rcc' was resolved. Included 'Completely Resected' and 'Very High-Risk' as defining clinical characteristics. Applied Title Case formatting based on retrieved rules.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case to the finalized medical indication phrase to ensure standard formatting for disease names and descriptors.""}, {""category"": ""Abbreviations"", ""subcategories"": [""Expansion""], ""reason"": ""Expanded 'RCC' to 'Renal Cell Carcinoma' and 'Pts' to 'Patients' (implicit in structure) for clarity.""}]","[{""component"": ""Renal Cell Cancer (Rcc)"", ""type"": ""Disease"", ""normalized_form"": ""Renal Cell Carcinoma"", ""rule_applied"": ""Standardization and Abbreviation Expansion""}, {""component"": ""Clear Cell Histology"", ""type"": ""Histology"", ""normalized_form"": ""Clear Cell Histology"", ""rule_applied"": ""Extraction of Histological Subtype""}, {""component"": ""Completely Resected"", ""type"": ""Treatment Status"", ""normalized_form"": ""Completely Resected"", ""rule_applied"": ""Extraction of Patient Status""}, {""component"": ""Very High-Risk"", ""type"": ""Risk Stratification"", ""normalized_form"": ""Very High-Risk"", ""rule_applied"": ""Extraction of Risk Category""}]",0.95,1.0,0.98,1.0,0
296082,"NSCLC, metastatic",A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration,lung disease,Lung Disease,Metastatic non-small cell lung cancer,True,session_title,0.98,"The session title 'NSCLC, metastatic' provides a clear, concise definition of the disease state. The abbreviation 'NSCLC' was expanded to 'non-small cell lung cancer' according to standard medical terminology rules. The modifier 'metastatic' was reordered to the beginning of the phrase to follow standard English clinical nomenclature.","[{""category"": ""Common Check points"", ""subcategories"": [""Abbreviations""], ""reason"": ""Abbreviations such as NSCLC must be expanded to their full form (Non-small cell lung cancer) for clarity.""}, {""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""The indication should be formatted in sentence case, capitalizing the first word and proper nouns only.""}, {""category"": ""Disease/Condition"", ""subcategories"": [""Ordering""], ""reason"": ""Adjectives indicating stage or condition (e.g., Metastatic) should precede the primary disease name.""}]","[{""component"": ""NSCLC"", ""type"": ""Disease"", ""normalized_form"": ""non-small cell lung cancer"", ""rule_applied"": ""Abbreviation Expansion""}, {""component"": ""metastatic"", ""type"": ""Stage"", ""normalized_form"": ""Metastatic"", ""rule_applied"": ""Adjective Reordering""}]",1.0,1.0,1.0,1.0,0
181510,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications,Childhood;;AML,Childhood Acute Myeloid Leukemia,Childhood Acute Myeloid Leukemia,True,Abstract Title,0.98,"The abstract title specifies 'Childhood AML'. 'AML' is a standard abbreviation for 'Acute Myeloid Leukemia'. 'Childhood' is a specific patient subgroup that distinguishes the condition from adult forms and is retained. The session title mentions 'Acute Myeloid Leukemias' generally, but the abstract is more specific.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Apply Title Case to the final indication string (e.g., capitalize significant words).""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Checked for exclusion keywords (e.g., 'Prior', 'Reversible') or modification rules (e.g., 'Associated', 'De Novo'). No exclusion rule matched 'Childhood', validating its retention.""}]","[{""component"": ""Childhood"", ""type"": ""Patient Subgroup"", ""normalized_form"": ""Childhood"", ""rule_applied"": ""Retention (No Exclusion Rule Found)""}, {""component"": ""AML"", ""type"": ""Disease Abbreviation"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Abbreviation Expansion""}]",1.0,1.0,1.0,1.0,0
181511,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML,AML,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",0.95,"The session title explicitly mentions 'Acute Myeloid Leukemias'. Following the 'Singular' rule (ID 8) from the 'Common Check points' category, the plural term 'Leukemias' is converted to 'Leukemia', resulting in 'Acute Myeloid Leukemia'. The abstract title mentions 'Monosomy7 AML', where AML is the abbreviation for the same disease and Monosomy7 is a cytogenetic marker/subgroup; the full disease name from the session title is preferred for the indication.","[{""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Used to normalize the plural term 'Leukemias' to the singular 'Leukemia' and ensure standard formatting.""}, {""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Used to ensure the output is in Title Case.""}]","[{""component"": ""Acute Myeloid Leukemias"", ""type"": ""Disease Name"", ""normalized_form"": ""Acute Myeloid Leukemia"", ""rule_applied"": ""Rule 8 (Singular)""}]",1.0,1.0,1.0,1.0,0
279835,Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe,RWD of CAR T-cell therapy in older adults: The UK experience,,,Hematological malignancies in older adults,True,Session Title and Abstract Title,0.9,"The input text explicitly mentions 'Hematology' and 'CAR T-cell therapy', which is used to treat blood cancers. Consequently, 'Hematological malignancies' is inferred as the condition. The specific patient population 'older adults' is explicitly stated in both titles and is retained as part of the indication.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Indication should be in sentence case.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Age""], ""reason"": ""Specific age groups (e.g., older adults) mentioned in the context must be included in the indication.""}, {""category"": ""Data Source Priority"", ""subcategories"": [""General""], ""reason"": ""Combine information from Session Title and Abstract Title to form a complete indication when individual sources are partial.""}]","[{""component"": ""Hematology"", ""type"": ""Therapeutic Area"", ""normalized_form"": ""Hematological malignancies"", ""rule_applied"": ""Inference from Context""}, {""component"": ""older adults"", ""type"": ""Population"", ""normalized_form"": ""older adults"", ""rule_applied"": ""Patient Sub-Group Retention""}]",1.0,1.0,0.95,1.0,0
197935,Poster Session I (In-Person),No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,,,15q11.2 BP1-BP2 Copy Number Variant,True,No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,0.95,"The input text describes a study on subjects ('Carriers') with a specific genetic condition ('15q11.2 BP1-BP2 Copy Number Variant'). The phrase 'No Signs of Neurodegenerative Effects' is a study finding (negative finding), not the indication. The term 'Carriers' describes the patient subgroup but the underlying medical indication/condition is the genetic variant itself. Title Case rules were applied to formatting.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case formatting to the indication, preserving gene/locus symbols '15q11.2' and 'BP1-BP2'.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Ensured the indication is in the singular form; 'Carriers' was interpreted as a population descriptor and excluded to isolate the condition.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Checked for patient subgroup modifiers; while 'Carrier' was not explicitly in the retrieved exclusion list, standard interpretation aligned with excluding population descriptors.""}]","[{""component"": ""15q11.2 BP1-BP2 Copy Number Variant"", ""type"": ""Genetic Condition"", ""normalized_form"": ""15q11.2 BP1-BP2 Copy Number Variant"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
148814,Myelodysplastic Syndromes - Clinical,A Phase 3 Study Of The Efficacy And Safety Of Luspatercept Versus Epoetin Alfa For The Treatment Of Anemia Due To Lower-Risk Mds In Esa-Naive Patients Requiring Rbc Transfusions (The Commands Trial),Lower-Risk;;Mds,Low-Risk Myelodysplastic Syndrome,Anemia;;Lower-Risk Myelodysplastic Syndrome,True,Myelodysplastic Syndromes - Clinical A Phase 3 Study Of The Efficacy And Safety Of Luspatercept Versus Epoetin Alfa For The Treatment Of Anemia Due To Lower-Risk Mds In Esa-Naive Patients Requiring Rbc Transfusions (The Commands Trial),0.95,"Extracted 'Anemia' and 'Lower-Risk Mds' from the text. Normalized 'Mds' to 'Myelodysplastic Syndrome' based on the session title 'Myelodysplastic Syndromes' and the Singular rule (Syndromes -> Syndrome). Applied Title Case formatting. Interpreted 'Due To' as a connector between a condition (Anemia) and a disease (MDS), warranting extraction of both entities, similar to the logic for 'Associated' rules where disease-associated conditions are split. Excluded 'Esa-Naive' and 'Requiring Rbc Transfusions' as they represent patient subgroups/characteristics rather than the core disease indication.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case to the extracted indications.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Applied Singular rule: 'Myelodysplastic Syndromes' converted to 'Myelodysplastic Syndrome'.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Evaluated 'Esa-Naive' and 'Requiring Rbc Transfusions' as patient characteristics to be excluded, consistent with general subgroup exclusion principles (e.g., 'Prior').""}]","[{""component"": ""Anemia"", ""type"": ""Condition"", ""normalized_form"": ""Anemia"", ""rule_applied"": ""Title Case""}, {""component"": ""Lower-Risk Mds"", ""type"": ""Disease"", ""normalized_form"": ""Lower-Risk Myelodysplastic Syndrome"", ""rule_applied"": ""Singular; Title Case; Abbreviation Expansion""}, {""component"": ""Esa-Naive"", ""type"": ""Patient Subgroup"", ""normalized_form"": ""Excluded"", ""rule_applied"": ""Patient Sub-Group Exclusion""}, {""component"": ""Requiring Rbc Transfusions"", ""type"": ""Patient Subgroup"", ""normalized_form"": ""Excluded"", ""rule_applied"": ""Patient Sub-Group Exclusion""}]",1.0,1.0,1.0,1.0,0
394576,Supportive Care,Prevention Of Taxane Chemotherapy Induced Nail Changes And Peripheral Neuropathy By Application Of Extremity Cooling: A Prospective Single Center Study With Intrapatient Comparison,Peripheral Neuropathy,Peripheral Neuropathy,Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy,True,abstract_title,0.95,"The indication was extracted from the abstract title as it provides the specific clinical focus. The phrase 'Prevention Of Taxane Chemotherapy Induced Nail Changes And Peripheral Neuropathy' clearly defines the prophylactic intent and the target conditions (nail changes, peripheral neuropathy) resulting from a specific cause (taxane chemotherapy). Study design details ('By Application Of...', 'A Prospective...') were removed.","[{""category"": ""Source Selection"", ""subcategories"": [""Hierarchy""], ""reason"": ""Abstract title preferred over session title for granularity.""}, {""category"": ""Common Check points"", ""subcategories"": [""General"", ""Casing""], ""reason"": ""Trim study design markers; Normalize casing to sentence case; Add hyphen to 'chemotherapy-induced'.""}]","[{""component"": ""Prevention of"", ""type"": ""Intent"", ""normalized_form"": ""Prevention of"", ""rule_applied"": ""Keep prophylactic intent""}, {""component"": ""Taxane Chemotherapy Induced"", ""type"": ""Etiology"", ""normalized_form"": ""taxane chemotherapy-induced"", ""rule_applied"": ""Hyphenate induced conditions""}, {""component"": ""Nail Changes And Peripheral Neuropathy"", ""type"": ""Condition"", ""normalized_form"": ""nail changes and peripheral neuropathy"", ""rule_applied"": ""Lowercase normalization""}]",1.0,0.98,1.0,1.0,0
394584,Supportive Care,Initial Geriatric Assessment And Chemotherapy Tolerability Treatment In Brazilian Patients With Malignant Neoplasm Of The Digestive System.,Malignant;;Neoplasm,Malignant Neoplasm,Malignant Neoplasm of the Digestive System,True,abstract_title,0.98,"The indication was extracted from the abstract title. The phrase 'Initial Geriatric Assessment And Chemotherapy Tolerability Treatment' describes the study intervention/scope, while 'Brazilian Patients' refers to the demographic population. The core condition is 'Malignant Neoplasm Of The Digestive System'. Per standard indication rules, demographics (nationality) are removed, and the text is formatted in Title Case with 'of' and 'the' lowercased.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To apply standard capitalization rules (Title Case) and handle prepositions.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Ethnicity/Nationality""], ""reason"": ""To identify and exclude non-essential demographic descriptors like 'Brazilian'.""}, {""category"": ""Disease/Condition"", ""subcategories"": [""General Extraction""], ""reason"": ""To isolate the pathological condition from the study methodology.""}]","[{""component"": ""Malignant Neoplasm"", ""type"": ""Disease Entity"", ""normalized_form"": ""Malignant Neoplasm"", ""rule_applied"": ""Core disease extraction""}, {""component"": ""Digestive System"", ""type"": ""Body System"", ""normalized_form"": ""Digestive System"", ""rule_applied"": ""Anatomical site specification""}]",1.0,1.0,1.0,1.0,0
230744,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers.,cancer-associated;;thrombosis;;biliary tract cancers,Cancer-Associated Thrombosis;;Biliary Tract Cancer,Biliary Tract Cancer,True,abstract_title,0.96,"The abstract title specifically focuses on 'biliary tract cancers'. Based on Rule 2 (Singular) and Rule 1 (Title Case), the plural phrase was converted to the singular, Title Cased form 'Biliary Tract Cancer'. The session title 'Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary' supports the classification within hepatobiliary oncology.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication uses Title Case formatting (Rule 1).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To convert plural disease terms ('cancers') to their singular form (Rule 2, 4, 6).""}]","[{""component"": ""biliary tract cancers"", ""type"": ""Disease"", ""normalized_form"": ""Biliary Tract Cancer"", ""rule_applied"": ""Singularize and Title Case""}]",1.0,1.0,1.0,1.0,0
197976,Poster Session I (In-Person),Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma,Trauma,Trauma,Early-Life Trauma Exposure,True,abstract_title,0.95,"The abstract title clearly identifies 'Early-Life Trauma Exposure' as the primary medical condition or context being studied. The text 'The Role of vmPFC in Resilience to Trauma' describes the investigative focus and outcome, not the indication itself. The extracted term was normalized to Title Case and verified for singular formatting based on the retrieved rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case as per standard medical conventions.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To verify the term is in the singular form and free of trailing spaces.""}]","[{""component"": ""Early-Life Trauma Exposure"", ""type"": ""Condition"", ""normalized_form"": ""Early-Life Trauma Exposure"", ""rule_applied"": ""Title Case conversion (Rule ID 7)""}]",1.0,1.0,0.95,1.0,0
296288,"Head and neck cancer, excluding thyroid",Real World Evidence of First-line Cetuximab (CX) plus Paclitaxel (PX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),Recurrent;;Metastatic;;Squamous Cell Carcinoma of the Head and Neck,Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),True,Abstract Title,0.98,"The abstract title provides a specific patient population diagnosis: 'Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)'. This is extracted as the primary indication. The session title is too broad ('Head and neck cancer'). The indication is normalized to Title Case as per the 'Common Check points - Casing' rule, keeping the abbreviation SCCHN in uppercase.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case formatting to the extracted indication string (capitalizing principal words, lowercasing prepositions).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Verified singular form usage and handling of abbreviations.""}]","[{""component"": ""Recurrent or Metastatic"", ""type"": ""Disease Stage/Modifier"", ""normalized_form"": ""Recurrent or Metastatic"", ""rule_applied"": ""Title Case""}, {""component"": ""Squamous Cell Carcinoma of the Head and Neck"", ""type"": ""Disease Name"", ""normalized_form"": ""Squamous Cell Carcinoma of the Head and Neck"", ""rule_applied"": ""Title Case""}, {""component"": ""SCCHN"", ""type"": ""Abbreviation"", ""normalized_form"": ""SCCHN"", ""rule_applied"": ""Preserve Acronyms""}]",1.0,1.0,1.0,1.0,0
148828,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,Validation Of Algorithms To Identify First-Line Therapy (Induction And Maintenance) For Multiple Myeloma For Use In Electronic Healthcare Databases,First-Line;;Multiple Myeloma,First-Line Multiple Myeloma,Multiple Myeloma,True,Abstract Title,1.0,"The abstract title explicitly mentions 'First-Line Therapy... For Multiple Myeloma', identifying it as the specific condition being studied. While the session title mentions 'Myeloma And Other Monoclonal Gammopathies', the abstract focuses specifically on Multiple Myeloma.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case as per Rule 1.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form where applicable, following Rule 2.""}]","[{""component"": ""Multiple Myeloma"", ""type"": ""Disease"", ""normalized_form"": ""Multiple Myeloma"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
230749,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Clinical utility of immunotherapy hyperprogressive genes in hepatocellular carcinoma patients.,hepatocellular carcinoma,Hepatocellular Carcinoma,Hepatocellular Carcinoma,True,Abstract Title,0.98,"The abstract title specifically identifies 'hepatocellular carcinoma patients' as the target population for the study. The session title provides a broader context (Gastrointestinal Cancer - Hepatobiliary), but the specific indication is hepatocellular carcinoma. Rules for Title Case were applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To check for singular vs plural forms and trailing spaces.""}]","[{""component"": ""hepatocellular carcinoma"", ""type"": ""Disease"", ""normalized_form"": ""Hepatocellular Carcinoma"", ""rule_applied"": ""Title Case (Rule ID 7)""}]",1.0,1.0,1.0,1.0,0
148829,Myeloma And Other Monoclonal Gammopathies - Clinical,A Clinical-Decision Tool To Improve The Strategy Of Multiple Myeloma Treatment,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,Abstract Title,0.95,"The abstract title explicitly focuses on 'Multiple Myeloma Treatment'. The term 'Multiple Myeloma' is extracted as the specific disease indication. Standard formatting rules (Title Case, Singular) are applied.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the indication is formatted in Title Case.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form.""}]","[{""component"": ""Multiple Myeloma"", ""type"": ""Disease"", ""normalized_form"": ""Multiple Myeloma"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
296292,Hepatocellular carcinoma (HCC),Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma,hepatocellular carcinoma,hepatocellular carcinoma,Hepatocellular Carcinoma,True,session_title,0.98,"The indication 'Hepatocellular carcinoma' was identified primarily from the session title. According to Rule 7 (Common Check points - Casing), the indication was formatted to Title Case, resulting in 'Hepatocellular Carcinoma'. The parenthetical abbreviation '(HCC)' was excluded in favor of the full disease name.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""Abbreviation""], ""reason"": ""To determine the capitalization standards and handling of abbreviations for medical indications.""}]","[{""component"": ""Hepatocellular carcinoma"", ""type"": ""Disease Name"", ""normalized_form"": ""Hepatocellular Carcinoma"", ""rule_applied"": ""Rule 7 (Title Case)""}]",1.0,1.0,1.0,1.0,0
279909,Pediatric hematology: Immunodeficiency-related lymphoproliferative disorders,Classification of immunodeficiency-related lymphoproliferative disorders,immunodeficiency-related lymphoproliferative disorders,Immunodeficiency-Related Lymphoproliferative Disorder,Immunodeficiency-Related Lymphoproliferative Disorder,True,abstract_title,0.95,"The indication was extracted from the abstract title 'Classification of immunodeficiency-related lymphoproliferative disorders'. Based on the retrieved rules for 'Common Check points', the indication was converted to Title Case (Rule ID 7) and the plural term 'disorders' was singularized to 'Disorder' (Rule ID 8/10), resulting in the standardized form.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine capitalization standards (Title Case).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To apply singularization rules to the disease term.""}]","[{""component"": ""Immunodeficiency-Related"", ""type"": ""Etiology/Modifier"", ""normalized_form"": ""Immunodeficiency-Related"", ""rule_applied"": ""Title Case""}, {""component"": ""Lymphoproliferative"", ""type"": ""Pathology"", ""normalized_form"": ""Lymphoproliferative"", ""rule_applied"": ""Title Case""}, {""component"": ""disorders"", ""type"": ""Disease Entity"", ""normalized_form"": ""Disorder"", ""rule_applied"": ""Singularization""}]",1.0,1.0,1.0,1.0,0
378207,Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden,Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL,CLL,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,True,session_title,0.98,"The session title explicitly identifies 'Chronic Lymphocytic Leukemia' (CLL) as the primary condition. The abstract further contextualizes the discussion around infections associated with this specific cancer. Per the retrieved rules, the indication is extracted in the singular form and formatted in Title Case.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To apply Title Case formatting to the extracted indication.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form.""}]","[{""component"": ""Chronic Lymphocytic Leukemia"", ""type"": ""Disease Name"", ""normalized_form"": ""Chronic Lymphocytic Leukemia"", ""rule_applied"": ""Title Case""}, {""component"": ""CLL"", ""type"": ""Abbreviation"", ""normalized_form"": ""Chronic Lymphocytic Leukemia"", ""rule_applied"": ""Abbreviation Expansion""}]",1.0,1.0,1.0,1.0,0
394614,Supportive Care,"Mortality Within 30 Days After Last Dose Of Intravenous Systemic Anti-Cancer Therapy: Single-Center, One-Year, Retrospective Analysis",,,Cancer,True,"Mortality Within 30 Days After Last Dose Of Intravenous Systemic Anti-Cancer Therapy: Single-Center, One-Year, Retrospective Analysis",0.95,"The input text describes a study on mortality following 'Systemic Anti-Cancer Therapy'. The underlying medical indication for this therapy is 'Cancer', which is derived from the therapy descriptor 'Anti-Cancer'. The indication is formatted to Title Case and singular form in accordance with the applied rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the indication is formatted in Title Case and Singular form, removing pluralizations if present.""}]","[{""component"": ""Anti-Cancer"", ""type"": ""Disease Context"", ""normalized_form"": ""Cancer"", ""rule_applied"": ""Extraction from therapy descriptor; Title Case conversion""}]",1.0,1.0,1.0,1.0,0
345465,Mouse Models of Human Cancer,A non-surgical approach to develop an orthotopic colorectal cancer mouse model,colorectal cancer,Colorectal Cancer,Colorectal Cancer,True,abstract_title,0.95,The abstract title explicitly identifies 'colorectal cancer' as the disease being modeled. The term 'orthotopic' refers to the methodology of the mouse model rather than a distinct clinical subtype of the disease itself for indication purposes. The indication was normalized to Title Case and Singular form according to the retrieved rules.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine the capitalization standard (Title Case).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To enforce singular formatting for disease terms.""}]","[{""component"": ""colorectal cancer"", ""type"": ""Disease"", ""normalized_form"": ""Colorectal Cancer"", ""rule_applied"": ""Title Case; Singular""}]",1.0,1.0,1.0,1.0,0
214394,MP58: Prostate Cancer: Detection & Screening VII,ATM mutations are associated with high-risk architectural features in men with familial prostate cancer,familial;;prostate cancer,Familial Prostate Cancer ,Familial prostate cancer,True,abstract_title,0.95,"The abstract title identifies the specific patient population as 'men with familial prostate cancer'. The indication is extracted by removing the demographic identifier 'men with' and retaining the specific disease subtype 'Familial'. 'ATM mutations' describes a biomarker associated with features within this group, rather than the indication itself in this context.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To determine standard capitalization (sentence case) and general formatting requirements.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""To identify rules for processing terms like 'men with' and determining if 'Familial' constitutes a valid subgroup.""}, {""category"": ""Gene Mutation"", ""subcategories"": [""General""], ""reason"": ""To assess whether 'ATM mutations' should be included in the indication name.""}]","[{""component"": ""men with"", ""type"": ""Patient Demographic"", ""normalized_form"": """", ""rule_applied"": ""Remove patient demographics""}, {""component"": ""familial"", ""type"": ""Disease Subtype"", ""normalized_form"": ""Familial"", ""rule_applied"": ""Capitalize first word, retain subtype""}, {""component"": ""prostate cancer"", ""type"": ""Disease"", ""normalized_form"": ""prostate cancer"", ""rule_applied"": ""Retain disease name in lowercase""}]",1.0,1.0,1.0,1.0,0
394619,Supportive Care,Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors,Advanced;;High Grade;;Ovarian Carcinoma,Advanced High Grade Ovarian Carcinoma,Venous Thromboembolism in Advanced High Grade Ovarian Carcinoma,True,abstract_title,0.92,"The indication was extracted from the abstract title. The phrase 'Venous Thromboembolism' represents the primary condition (event) being studied within the context of 'Advanced High Grade Ovarian Carcinoma' (patient population). The phrase 'In Patients With' was standardized to 'in'. The parenthetical abbreviations '(Vte)' and '(Ahgoc)' were removed to produce a clean, normalized indication string. The treatment context 'Receiving Parp Inhibitors' was excluded from the primary indication name as it denotes the specific study cohort/intervention arm rather than the disease indication itself, although the indication implies this specific sub-population.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Applied Title Case formatting: Capitalized clinically significant words (Venous, Thromboembolism, Advanced, High, Grade, Ovarian, Carcinoma) and kept prepositions (in) lowercase.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""Analyzed title for specific subgroup modifiers (e.g., 'Associated', 'Persistent', 'De Novo'). None found. The indication was constructed by combining the condition and the underlying disease context.""}]","[{""component"": ""Venous Thromboembolism"", ""type"": ""Condition/Event"", ""normalized_form"": ""Venous Thromboembolism"", ""rule_applied"": ""Title Case transformation; Parentheses removal""}, {""component"": ""Advanced High Grade Ovarian Carcinoma"", ""type"": ""Patient Population"", ""normalized_form"": ""Advanced High Grade Ovarian Carcinoma"", ""rule_applied"": ""Title Case transformation; Parentheses removal""}]",1.0,1.0,0.95,1.0,0
148861,Myeloma And Other Monoclonal Gammopathies - Clinical,Lenalidomide Versus Thalidomide Or Bortezomib As Maintenance Regimen For Non-Transplant Patients With Multiple Myeloma: Multi-Center Real World Experiences In China,Multiple Myeloma,Multiple Myeloma,Multiple myeloma,True,Lenalidomide Versus Thalidomide Or Bortezomib As Maintenance Regimen For Non-Transplant Patients With Multiple Myeloma: Multi-Center Real World Experiences In China,0.95,"The abstract title explicitly identifies 'Multiple Myeloma' as the condition being treated. The phrase 'Non-Transplant Patients' defines a subgroup, and 'Maintenance Regimen' defines the line of therapy, but the core indication is the disease itself. 'Patients With' is removed per standard cleaning rules.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the disease name follows standard sentence casing (Multiple myeloma) and to remove non-essential text like 'Patients With'.""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""General""], ""reason"": ""To evaluate whether 'Non-Transplant Patients' should be part of the core indication string or treated as a modifier.""}]","[{""component"": ""Multiple Myeloma"", ""type"": ""Disease"", ""normalized_form"": ""Multiple myeloma"", ""rule_applied"": ""Standard Disease Extraction""}, {""component"": ""Non-Transplant Patients"", ""type"": ""Patient Subgroup"", ""normalized_form"": ""Non-transplant eligible"", ""rule_applied"": ""Subgroup Identification""}, {""component"": ""Maintenance Regimen"", ""type"": ""Therapy Line"", ""normalized_form"": ""Maintenance therapy"", ""rule_applied"": ""Therapy Context""}]",0.9,1.0,1.0,1.0,0
181632,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II,Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts),Relapsed;;Refractory;;Non-Hodgkin Lymphoma,Relapsed/Refractory Non-Hodgkin Lymphoma,relapsed or refractory non-Hodgkin lymphoma,True,abstract_title,0.98,The indication was extracted from the abstract title. The phrase 'Relapsed/Refractory (R/R)' was normalized to 'relapsed or refractory'. The abbreviation 'NHL' was expanded to 'non-Hodgkin lymphoma'. Casing was adjusted to lowercase 'lymphoma' while preserving the proper noun 'Hodgkin'.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To ensure the disease name is lowercased except for proper nouns (Hodgkin).""}, {""category"": ""Patient Sub-Group"", ""subcategories"": [""Refractory/Relapsed""], ""reason"": ""To standardize 'Relapsed/Refractory' and 'R/R' to the full form 'relapsed or refractory'.""}, {""category"": ""Common Check points"", ""subcategories"": [""Abbreviation""], ""reason"": ""To expand the abbreviation 'NHL' to 'non-Hodgkin lymphoma'.""}]","[{""component"": ""Relapsed/Refractory (R/R)"", ""type"": ""Patient Population"", ""normalized_form"": ""relapsed or refractory"", ""rule_applied"": ""Expand and standardize relapse/refractory status""}, {""component"": ""Non-Hodgkin Lymphoma (NHL)"", ""type"": ""Disease"", ""normalized_form"": ""non-Hodgkin lymphoma"", ""rule_applied"": ""Expand abbreviation and apply sentence casing (preserving proper nouns)""}]",1.0,1.0,1.0,1.0,0
198019,Poster Session I (In-Person),"Hippocampal volume, FKBP5 genetic risk alleles, and childhood trauma interact to increase vulnerability to chronic multisite musculoskeletal pain",childhood;;trauma;;chronic;;multisite musculoskeletal pain,Chronic Multisite Musculoskeletal Pain;;Childhood Trauma,Chronic Multisite Musculoskeletal Pain,True,abstract_title,0.98,"The abstract title explicitly studies factors interacting to increase vulnerability to 'chronic multisite musculoskeletal pain'. This phrase represents the medical condition (indication) under investigation. According to the retrieved rules, the indication is formatted in Title Case.","[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""To determine the capitalization standard, which requires Title Case for disease names.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""To ensure the indication is in the singular form where applicable.""}]","[{""component"": ""chronic"", ""type"": ""Chronicity"", ""normalized_form"": ""Chronic"", ""rule_applied"": ""Title Case""}, {""component"": ""multisite"", ""type"": ""Topography"", ""normalized_form"": ""Multisite"", ""rule_applied"": ""Title Case""}, {""component"": ""musculoskeletal"", ""type"": ""System"", ""normalized_form"": ""Musculoskeletal"", ""rule_applied"": ""Title Case""}, {""component"": ""pain"", ""type"": ""Condition"", ""normalized_form"": ""Pain"", ""rule_applied"": ""Title Case""}]",1.0,1.0,1.0,1.0,0
329094,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II,"Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC(r)) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)",Relapsed;;Refractory;;Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,True,"Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC(r)) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)",0.98,The abstract title explicitly states the study is for 'Relapsed/Refractory Multiple Myeloma'. This matches the pattern of [Condition Modifier] + [Disease Name]. Rules for Title Case were applied to ensure standard formatting.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Rule ID 7: Convert medical-indication phrase to Title Case (capitalize first letter of clinically significant words).""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Rule ID 8: Ensure the indication is in the singular form.""}]","[{""component"": ""Relapsed/Refractory"", ""type"": ""Patient Subgroup/Modifier"", ""normalized_form"": ""Relapsed/Refractory"", ""rule_applied"": ""Title Case (Rule ID 7)""}, {""component"": ""Multiple Myeloma"", ""type"": ""Disease Name"", ""normalized_form"": ""Multiple Myeloma"", ""rule_applied"": ""Title Case (Rule ID 7)""}]",1.0,1.0,1.0,1.0,0
148870,Myeloma And Other Monoclonal Gammopathies - Clinical,Real World Evidence Of Carfilzomib In Relapsed Refractory Multiple Myeloma (Rrmm),Relapsed;;Refractory;;Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,Relapsed Refractory Multiple Myeloma,True,abstract_title,0.98,The indication was extracted from the abstract title as it provided a specific disease state including patient subgroup modifiers ('Relapsed Refractory'). The session title was broader. The acronym '(Rrmm)' was removed for clarity. Title Case was applied in accordance with the retrieved rules.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing""], ""reason"": ""Converted to Title Case as per Rule ID 7.""}, {""category"": ""Common Check points"", ""subcategories"": [""General""], ""reason"": ""Ensured singular form where applicable as per Rule ID 8.""}]","[{""component"": ""Relapsed Refractory"", ""type"": ""Patient Sub-Group"", ""normalized_form"": ""Relapsed Refractory"", ""rule_applied"": ""Extraction""}, {""component"": ""Multiple Myeloma"", ""type"": ""Disease"", ""normalized_form"": ""Multiple Myeloma"", ""rule_applied"": ""Extraction""}, {""component"": ""(Rrmm)"", ""type"": ""Acronym"", ""normalized_form"": ""Removed"", ""rule_applied"": ""Cleanup""}]",1.0,1.0,1.0,1.0,0
312715,Tumor Cell And Molecular Biology: Drug Resistance,Establishment And Characterization Of Two Er+/Her2- Xpdx Models Developed Sequentially Before And After Acquired Resistance To The Cdk4/6 Inhibitor Palbociclib From A Patient With Metastatic Breast Cancer,Metastatic;;Breast Cancer,Metastatic Breast Cancer,Metastatic breast cancer,True,abstract_title,0.98,The indication was explicitly identified in the abstract title as the condition of the patient from whom the models were derived ('From A Patient With Metastatic Breast Cancer'). The extraction focuses on the disease state.,"[{""category"": ""Common Check points"", ""subcategories"": [""Casing"", ""General""], ""reason"": ""To ensure the indication follows standard sentence case and formatting rules.""}, {""category"": ""Indication"", ""subcategories"": [""Oncology"", ""Breast""], ""reason"": ""To validate specific terminology related to breast cancer stages and subtypes.""}]","[{""component"": ""Metastatic"", ""type"": ""Adjective/Stage"", ""normalized_form"": ""Metastatic"", ""rule_applied"": ""Preserve modifier""}, {""component"": ""Breast Cancer"", ""type"": ""Disease Name"", ""normalized_form"": ""breast cancer"", ""rule_applied"": ""Convert to sentence case""}]",1.0,1.0,1.0,1.0,0
